

1. Underwood M. A Treatise of Children With General Directions for Management of Infants From Birth. 2nd ed. London, England: Matthews; 1789.
2. Poliomyelitis Vaccine Evaluation Center. Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine. Ann Arbor, MI: Edwards Brothers; 1957.
3. World Health Assembly. Global Eradication of Poliomyelitis by the Year 2000. Geneva, Switzerland: World Health Organization; 1988.
4. Paul JR. A History of Poliomyelitis. New Haven, CT: Yale University Press; 1971.
5. Heine J. Beobachtungen über Lähmungszustände der unteren Extremitäten und deren Behandlung. Stuttgart, Germany: Köhler; 1840.
6. West C. On some forms of paralysis incidental to infancy and childhood. Lond Med Gaz. 32:829–836, 1843.
7. Rilliet F. De la paralysie essentielle chez les enfants. Gaz Med (Paris). 6:681–704, 1851.
8. de Boulogne D. De l'Electrisation Localisée et de son Application a la Physiologie, a la Pathologie et a la Thérapeutique. Paris, France: Baillières; 1855.
9. von Heine J. Spinale Kinderlähmung. Stuttgart, Germany: Cotta; 1860.
10. Charcot JM. Groupe des myopathies de cause spinal: paralysie infantile. Rev Phot Hop. 4:1–36, 1872.
11. Frey A. Ein Fall von subakuter Lähmung Erwachsener, wahrscheinlich Poliomyelitis. Berl Klin Wochenschr. 11:549–566, 1874.
12. Wickman I. Beiträge zur Kenntniss der Heine-Medinschen Krankheit (Poliomyelitis acuta und verwandte Erkrankungen). Berlin, Germany: Karger; 1907.
13. Leegaard C. Die akute Poliomyelitis in Norwegen. Dtsch Z Nervenheilkd. 53:145–262, 1890.
14. Wickman I. Studien über Poliomyelitis acuta: Zugleich ein Beiträge zur Kenntniss der Myelitis acuta. Arb Path Inst Univ Helsingfors, Vol. 1. Berlin, Germany: Karger; 1905.
15. Caverly CS. Preliminary report of an epidemic of paralytic disease, occurring in Vermont, in the summer of 1894. Yale Med J. i: 1–5, 1894–1895.
16. Lavinder CH, Freeman AW, Frost WH. Epidemiologic studies of poliomyelitis in New York City and the northeastern United States during the year 1916. Public Health Bull (Wash). 91, 1918.
17. Landsteiner K, Popper E. Mikroskopische Präparate von einem menschlichen und zwei Affenrückenmarken. Wien Klin Wochenschr. 21:1830, 1908.
18. Burnet FM, Macnamara J. Immunological differences between strains of poliomyelitis virus. Br J Exp Pathol. 12:57–61, 1931.
19. Committee on Typing of the National Foundation for Infantile Paralysis. Immunologic classification of poliomyelitis viruses: a cooperative program for the typing of one hundred strains. Am J Hyg. 54:191–274, 1951.

20. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. *Science*. 109:85–87, 1949.
21. Hammon WM, Coriell LI, Stokes J. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis, I: plan of controlled field tests and results of 1951 pilot study in Utah. *JAMA*. 150:739–749, 1952.
22. Sutter RW, Pallansch MA, Sawyer LA, et al. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. *Ann N Y Acad Sci*. 754:289–299, 1995.
23. Brown GC, Rabson AS, Schieble JH. The effect of gamma globulin on subclinical infection in familial associates of poliomyelitis cases, II: serological studies and virus isolations from pharyngeal secretions. *J Immunol*. 74:71–80, 1955.
24. Horstmann DM, McCollum RW, Mascola AD. Viremia in human poliomyelitis. *J Exp Med*. 99:355–369, 1954.
25. McKay HW, Fodor AR, Kokko UP. Viremia following administration of live poliovirus vaccines. *Am J Public Health*. 53:274–285, 1963.
26. Nathanson N, Bodian D. Experimental poliomyelitis following intramuscular virus injection, III: the effect of passive antibody on paralysis and viremia. *Bull Johns Hopkins Hosp*. 111:198–220, 1962.
27. Morgan IM. Immunization of monkeys with formalin-inactivated poliomyelitis viruses. *Am J Epidemiol*. 48:394–406, 1948.
28. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. *J Infect Dis*. 151:420–436, 1985.
29. Drinker P, Shaw LA. Apparatus for prolonged administration of artificial respiration, I: a design for adults and children. *J Clin Invest*. 7:229–247, 1929.
30. Sabin AB. Paralytic consequences of poliomyelitis infection in different parts of the world and in different population groups. *Am J Public Health*. 41:1215–1230, 1951.
31. Greenberg M, Siegel M, Magee MC. Poliomyelitis in New York City, 1949. *N Y State J Med*. 50:1119–1123, 1950.
32. Sabin AB. Epidemiologic patterns of poliomyelitis in different parts of the world. In: *Poliomyelitis: Papers and Discussions Presented at the First International Poliomyelitis Conference*. Philadelphia, PA: JB Lippincott; 1949: 3–33.
33. Das AN. *A Study of the Trend of the Age Selection of Poliomyelitis in the United States Since 1910*. Baltimore, MD: Johns Hopkins University; 1932.
34. Olin G. The epidemiologic pattern of poliomyelitis in Sweden from 1905 to 1950. In: *Poliomyelitis: Papers and Discussions Presented at the Second International Poliomyelitis Conference*. Philadelphia, PA: JB Lippincott; 1951, 367–375.
35. Paul JR. *The National Foundation for Infantile Paralysis In: A History of Poliomyelitis*. New Haven, CT: Yale University Press; 1971, 308–323.

36. Eggers HJ. History of poliomyelitis and poliomyelitis research. In: Semler BL, Wimmer E, (eds). *Molecular Biology of Picornaviruses*. Washington, DC: American Society for Microbiology; 2002, 3–14.
37. Hull HF, Ward NA, Hull BP, et al. Paralytic poliomyelitis: seasoned strategies, disappearing disease. *Lancet*. 343:1331–1337, 1994.
38. de Quadros CA, Hersh BS, Olive JM, et al. Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988–1995. *J Infect Dis*. 175(Suppl 1):S37–S42, 1997.
39. World Health Organization. Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2011 (Data received in WHO headquarters as of 13 March 2012). *Wkly Epidemiol Rec*. 87:123–128, 2012.
40. de Quadros CA. Global eradication of poliomyelitis and measles: another quiet revolution. *Ann Intern Med*. 127:156–158, 1997.
41. Foege WH. A world without polio: “Future generations will know by history only....” *JAMA*. 270:1859–1860, 1993.
42. Horstmann DM. Clinical aspects of acute poliomyelitis. *Am J Med*. 6:592–605, 1949.
43. Horstmann DM. Poliomyelitis: severity and type of disease in different age groups. *Ann N Y Acad Sci*. 61:956–967, 1955.
44. Paul JR. Clinical epidemiology of poliomyelitis. *Medicine (Baltimore)*. 20:495–520, 1941.
45. Gelfand HM, LeBlanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana, II: description and analysis of episodes of infection observed in study households. *Am J Hyg*. 65:367–385, 1957.
46. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. *Am J Epidemiol*. 172:1213–1229, 2010.
47. Draper G. *Acute Poliomyelitis*. Philadelphia, PA: Blakiston’s; 1917.
48. Bodian D. Poliomyelitis: pathogenesis and histopathology. In: Rivers TM, Horsfall FL, (eds). *Viral and Rickettsial Infections of Man*. Philadelphia, PA: JB Lippincott; 1959. 479–498.
49. Bodian D, Horstmann DM. Polioviruses. In: Horsfall FL, Tamm I, (eds). *Viral and Rickettsial Infections of Man*, 4th ed. Philadelphia, PA: JB Lippincott; 1965, 430–473.
50. Morens DM, Pallansch MA, Moore M. Polioviruses and other enteroviruses. In: Belshe RB, (ed). *Textbook of Human Virology*, 2nd ed. St Louis, MO: Mosby; 1991, 427–497.
51. Sabin AB. Poliomyelitis. In: Braude AI, Davis CE, Fierer J, (eds). *International Textbook of Medicine, Vol II. Infectious Diseases and Medical Microbiology*, 2nd ed. Philadelphia, PA: WB Saunders; 1986, 1147–1161.
52. Ramlow J, Alexander M, LaPorte R, et al. Epidemiology of postpolio syndrome. *Am J Epidemiol*. 136:769–786, 1992.

53. Dalakas MC, Sever JL, Madden DL, et al. Late post-poliomyelitis muscular atrophy: clinical, virological and immunological studies. *Rev Infect Dis.* 6(Suppl 2):S562–S567, 1984.
54. Dalakas MC, Bartfeld H, Kurland LT. The post-polio syndrome: advances in the pathogenesis and treatment: conference proceedings: Bethesda, Maryland, April 27–30, 1994. *Ann N Y Acad Sci.* 753:1–412, 1995.
55. Racaniello VR. Picornaviridae: the viruses and their replication. In: Knipe DM, Howley PM, Cohen JI, et al., eds. *Fields Virology.* 6 ed. Philadelphia: Lippincott Williams and Wilkins; 2013:453-489.
56. Oberste MS, Gerber SI. Enteroviruses and parechoviruses: echoviruses, coxsackieviruses, and others. In: Kaslow RA, Stanberry LR, Leduc JW, eds. *Viral Infections of Humans.* 5th ed. New York, NY: Springer; 2014:225-252.
57. Kew OM. Enteroviruses: polio. In: Kaslow RA, Stanberry LR, Leduc JW, eds. *Viral Infections of Humans.* 5th ed. New York, NY: Springer; 2014:277-336.
58. Hogle JM, Chow M, Filman DJ. The three-dimensional structure of poliovirus at 2.9 Å resolution. *Science.* 1985;229:1358-1365.
59. Melnick JL. Poliovirus and other enteroviruses. In: Evans AS, Kaslow RA, eds. *Viral Infections of Humans, Epidemiology and Control.* 4th ed. New York, NY: Plenum; 1997:583-663.
60. Le Bouvier GL. The D to C change in poliovirus particles. *Br J Exp Pathol.* 1959;40:605-620.
61. Wallis C, Melnick JL. Cationic stabilization—a new property of enteroviruses. *Virology.* 1962;16:504-506.
62. Melnick JL, Ashkenazi A, Midulla VC, Wallis C, Bernstein A. Immunogenic potency of magnesium chloride-stabilized oral poliovaccine. *JAMA.* 1963;185:406-408.
63. Sutter RW, Kew OM, Cochi SL, et al. Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA, eds. *Vaccines.* 6th ed. London, UK: W.B. Saunders; 2013:598-645.
64. Toyoda H, Kohara M, Kataoka Y, et al. Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. *J Mol Biol.* 1984;174:561-585.
65. Guillot S, Caro V, Cuervo N, et al. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. *J Virol.* 2000;74:8434-8443.
66. Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. *Science.* 2002;296:356-359.
67. Brown B, Oberste MS, Maher K, et al. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the non-capsid coding region. *J Virol.* 2003;77:8973-8984.

68. Liu H-M, Zheng D-P, Zhang L-B, et al. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. *J Virol.* 2003;77:10994-11005.
69. Yang C-F, Naguib T, Yang S-J, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt, 1983 to 1993. *J Virol.* 2003;77:8366-8377.
70. Minor PD. Antigenic structure of picornaviruses. *Curr Top Microbiol Immunol.* 1990;161:121-154.
71. Minor PD, Almond JW. Poliovirus vaccines: molecular biology and immune response. In: Semler BL, Wimmer E, eds. *Molecular Biology of Picornaviruses.* Washington, DC: ASM Press; 2002:381-390.
72. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. *Cell.* 56:855-865, 1989.
73. Gromeier M, Nomoto A. Determinants of poliovirus pathogenesis. In: Semler BL, Wimmer E, eds. *Molecular Biology of Picornaviruses.* Washington, DC: ASM Press; 2002:367-379.
74. Hogle JM. Poliovirus cell entry: Common structural themes in viral cell entry pathways. *Annu Rev Microbiol.* 2002;56:677-702.
75. Takai Y, Miyoshi J, Ikeda W, et al. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. *Nat Rev Mol Cell Biol.* 2008;9:603-615.
76. Maier MK, Seth S, Czeloth N, et al. The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. *Eur J Immunol.* 2007;37:2214-2225.
77. Bodian D, Morgan IM, Howe HA. Differentiation of types of poliomyelitis viruses, III: the grouping of fourteen strains into three basic immunologic types. *Am J Hyg.* 49:234-245, 1949.
78. Committee on Typing of the National Foundation for Infantile Paralysis. Immunologic classification of poliomyelitis viruses: a cooperative program for the typing of one hundred strains. *Am J Hyg.* 1951;54:191-204.
79. Minor PD, Dunn G, Evans DMA, et al. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. *J Gen Virol.* 1989;70:1117-1123.
80. Lentz KN, Smith AD, Geisler SC, et al. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. *Structure.* 1997;5:961-978.
81. Page GS, Mosser AG, Hogle JM, et al. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. *J Virol.* 1988;62:1781-1794.
82. Filman DJ, Syed R, Chow M, et al. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. *EMBO J.* 1989;8:1567-1579.

83. Nakano JH, Hatch MH, Thieme ML, et al. Parameters for differentiating vaccine-derived and wild poliovirus strains. *Prog Med Virol.* 1978;24:78-206.
84. Osterhaus AD, van Wezel AL, Hazendonk TG, et al. Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. *Intervirology.* 1983;20:129-136.
85. Huovilainen A, Kinnunen L, Ferguson M, et al. Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak. *J Gen Virol.* 1988;69:1941-1948.
86. Martín J, Dunn G, Hull R, et al. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. *J Virol.* 2000;74:3001-3010.
87. Shulman L, Manor J, Handsher R, et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. *J Clin Microbiol.* 2000;38:3729-3734.
88. Yakovenko ML, Cherkasova EA, Rezapkin GV, et al. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. *J Virol.* 2006;80:2641-2653.
89. Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. *J Virol.* 2008;82:4429-4440.
90. Odoom JK, Yunus Z, Dunn G, et al. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. *J Virol.* 2008;82:9179-9190.
91. DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. *N Engl J Med.* 364:2316–2323, 2011.
92. Harber J, Bernhardt G, Lu H-H, et al. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. *Virology.* 1995;214:559-570.
93. He Y-N, Bowman VD, Mueller S, et al. Interaction of the poliovirus receptor with poliovirus. *Proc Natl Acad Sci U S A.* 2000;97:79-84.
94. Armstrong C. The experimental transmission of poliomyelitis to the Eastern cotton rat, *Sigmodon hispidus hispidus*. *Public Health Rep.* 54:1719–1721, 1939.
95. Kessel JF, Pait CF. Differentiation of three groups of poliomyelitis virus. *Proc Soc Exp Biol Med.* 70:315–316, 1949.
96. Melnick JL. Antigenic crossings within poliovirus types. *Proc Soc Exp Biol Med.* 1955;89:131-133.
97. Uhlig J, Wieggers K, Dernick R. A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal-antibody. *Virology.* 1990;178:606-610.

98. Chen Z, Chumakov K, Dragunsky E, et al. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. *J Virol.* 85:4354–4362, 2011.
99. Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010.
100. Wimmer E, Paul A. The making of a picornavirus genome. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:33-55.
101. Arita M, Koike S, Aoki J, Horie H, Nomoto A. Interaction of poliovirus with its purified receptor and conformational alteration of the virion. *J Virol.* 1998;72:3578-3586.
102. Belnap DM, McDermott BM, Filman DJ, et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. *Proc Natl Acad Sci U S A.* 2000;97:73-78.
103. He Y, Mueller S, Chipman PR, et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. *J Virol.* 2003;77:4827-4835.
104. Bergelson JM. Receptors. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:73-86.
105. Levy H, Bostina M, Filman DJ, et al. Cell entry: a biochemical and structural perspective. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:87-104.
106. Palmenberg A, Neubauer D, Skern T. Genome organization and encoded proteins. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:3-17.
107. Martínez-Salas E, Ryan MD. Translation and protein processing. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:141-161.
108. Dougherty JD, Park N, Gustin KE, Lloyd RE. Interference with cellular gene expression. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:165-180.
109. Kirkegaard K, Semler BL. Genome replication II: the process. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:127-140.
110. Rozovics JM, Semler BL. Genome replication I: the players. In: Ehrenfeld E, Domingo E, Roos R, eds. *The Picornaviruses*. Washington, DC: ASM Press; 2010:107-125.
111. Bodian D. Histopathologic basis of clinical findings in poliomyelitis. *Am J Med.* 1949;6:563-578.
112. Freistadt MS, Stoltz DA, Eberle KE. Role of poliovirus receptors in the spread of infection. *Ann N Y Acad Sci.* 753:37–47, 1995.
113. Gromeier M, Wimmer E. Mechanisms of injury-provoked poliomyelitis. *J Virol.* 72:5056–5060, 1998.
114. Racaniello VR, Ren R. Poliovirus biology and pathogenesis. *Curr Top Microbiol Immunol.* 206:305–325, 1996.

115. Freistadt MS, Fleit HB, Wimmer E. Poliovirus receptor on human blood cells: a possible extraneural site of poliovirus replication. *Virology*. 195:798–803, 1993.
116. Bodian D, Paffenbarger RS. Poliomyelitis infection in households: frequency of viremia and specific antibody response. *Am J Hyg*. 60:83–98, 1954.
117. Mueller S, Wimmer E, Cello J. Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. *Virus Res*. 111:175–193, 2005.
118. Nathanson N. The pathogenesis of poliomyelitis: what we don't know. *Adv Virus Res*. 71:1–50, 2008.
119. Koike S, Nomoto A. Poliomyelitis. In: Ehrenfeld E, Domingo E, Roos R, (eds). *The Picornaviruses*. Washington, DC: ASM Press; 2010, 339–351.
120. Andrus JK, de Quadros CA, Olive JM, et al. Screening of cases of acute flaccid paralysis for poliomyelitis eradication: ways to improve specificity. *Bull World Health Organ*. 70:591–596, 1992.
121. Dietz V, Lezana M, Garcia Sancho C, et al. Predictors of poliomyelitis case confirmation at initial clinical evaluation: implications for poliomyelitis eradication in the Americas. *Int J Epidemiol*. 21:800–806, 1992.
122. Biellik RJ, Bueno H, Olive JM, et al. Poliomyelitis case confirmation: characteristics for use by national eradication programmes. *Bull World Health Organ*. 70:79–84, 1992.
123. Patriarca PA, Linkins RW, Sutter RW, et al. Optimal schedule for the administration of oral poliovirus vaccine. In: Kurstak E, (eds). *Measles and Poliomyelitis: Vaccine, Immunization, and Control*. Vienna, Austria: Springer-Verlag; 1993, 303–313.
124. Melnick JL. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields BN, Knipe DM, Howley PM, eds. *Fields Virology*. Third ed. Philadelphia, PA: Lippincott-Raven; 1996:655-712.
125. World Health Organization. *Polio laboratory manual*, 4th edition. Geneva, Switzerland: World Health Organization; 2004.
126. McAllister RM, Mclnyk J, Finklestein JZ, et al. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. *Cancer*. 1969;24:520-526.
127. Wood DJ, Hull B. L20B cells simplify culture of polioviruses from clinical samples. *J Med Virol*. 1999;58:188-192.
128. Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. *J Infect Dis*. 1997;175:S176-S82.
129. Kilpatrick DR, Nottay B, Yang C-F, et al. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. *J Clin Microbiol*. 1996;34:2990-2996.

130. Kilpatrick DR, Nottay B, Yang C-F, et al. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. *J Clin Microbiol.* 1998;36:352-357.
131. Kilpatrick DR, Yang C-F, Ching K, et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. *J Clin Microbiol.* 2009;47:1939-1941.
132. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses—worldwide, January 2008–June 2009. *MMWR Morb Mortal Wkly Rep.* 2009;58:950-954.
133. Kilpatrick DR, Ching K, Iber J, et al. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. *J Clin Microbiol.* 2004;42:4313-4315.
134. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, April 2011–June 2012. *MMWR Morb Mortal Wkly Rep.* 2012;61:741-746.
135. Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM. Geographic distribution of wild poliovirus type 1 genotypes. *Virology.* 1987;160:311-322.
136. Jegouic S, Joffret M-L, Blanchard C, et al. Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. *PLoS Pathog.* 2009;5:e1000412.
137. Burns C, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. *J Virol.* 2013;87:4907-4922.
138. Manor Y, Handsher R, Halmut T, et al. A double-selective tissue culture system for isolation of wild-type poliovirus from sewage applied in a long-term environmental surveillance. *Appl Environ Microbiol.* 1999;65:94-97.
139. Melnick JL, Mordhorst CH, Pervikov Y. Worldwide use of LBM combination pools for typing enteroviruses. *Bull World Health Organ.* 67:327–332, 1989.
140. Asghar H, Diop OM, Weldegebriel G, et al. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. *J Infect Dis.* 2014;210 Suppl 1:S294-S303.
141. Pöyry T, Stenvik M, Hovi T. Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. *Appl Environ Microbiol.* 1988;54:371-374.
142. Böttiger M, Herrstrom E. Isolation of polioviruses from sewage and their characteristics: experience over two decades in Sweden. *Scand J Infect Dis.* 1992;24:151-155.
143. van der Avoort HG, Reimerink JH, Ras A, Mulders MN, van Loon AM. Isolation of epidemic poliovirus from sewage during the 1992–3 type 3 outbreak in The Netherlands. *Epidemiol Infect.* 1995;114:481-491.

144. Manor Y, Handsher R, Halmut T, et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian Authority. *J Clin Microbiol.* 1999;37:1670-1675.
145. World Health Organization. Tracking progress towards global polio eradication, 2010–2011. *Wkly Epidemiol Rec.* 2012;87:153-160.
146. Yoshida H, Horie H, Matsuura K, et al. Prevalence of vaccine-derived polioviruses in the environment. *J Gen Virol.* 2002;83:1107-1101.
147. Shulman LM, Mendelson E, Anis E, et al. Laboratory challenges in response to silent introduction and sustained transmission of wild poliovirus type 1 in Israel during 2013. *J Infect Dis.* 2014;210:S304-S314.
148. Kopel E, Kaliner E, Grotto I. Lessons from a public health emergency—importation of wild poliovirus to Israel. *N Engl J Med.* 2014;371:981-983.
149. El Bassioni L, Barakat I, Nasr E, et al. Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. *Am J Epidemiol.* 2003;158:807-815.
150. Centers for Disease Control and Prevention. Progress towards poliomyelitis eradication—Egypt, 2003–2004. *MMWR Morb Mortal Wkly Rep.* 2004;53:820-822.
151. Hovi T, Blomqvist S, Nasr E, et al. Environmental surveillance of wild poliovirus circulation in Egypt—balancing between detection sensitivity and workload. *J Virol Methods.* 2005;126:127-134.
152. Deshpande JM, Shetty SJ, Siddiqui ZA. Environmental surveillance system to track wild poliovirus transmission. *Appl Environ Microbiol.* 2003;69:2919-2927.
153. Alam MM, Shaikat S, Sharif S, et al. Detection of multiple cocirculating wild poliovirus type 1 lineages through environmental surveillance: impact and progress during 2011-2013 in Pakistan. *J Infect Dis.* 2014;210 Suppl 1:S324-S332.
154. Etsano A, Gunnala R, Shuaib F, et al. Progress toward poliomyelitis eradication—Nigeria, January 2013–September 2014. *MMWR Morb Mortal Wkly Rep.* 2014;63:1059-1063.
155. Kew OM, Cochi SL, Jafari HS, et al. Possible eradication of wild poliovirus type 3—worldwide, 2012. *MMWR Morb Mortal Wkly Rep.* 2014;63:1031-1033.
156. Más Lago P, Gary HE Jr, Pérez LS, et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. *Int J Epidemiol.* 2003;32:772-777.
157. Huang Q, Greening G, Baker MG, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. *Lancet.* 366:394–396, 2005.
158. Wahjuhono G, Revolusiana, Widhiastuti D, et al. Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: Summary of coverage, immunity and environmental surveillance. *J Infect Dis.* 2014;210(Suppl 1):S347-S352.

159. Tambini G, Andrus JK, Marques E, et al. Direct detection of wild poliovirus transmission by stool surveys of healthy children and analysis of community wastewater. *J Infect Dis.* 1993;168:1510-1514.
160. Albrecht P, Enterline JC, Boone EJ, et al. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. *J Biol Stand.* 1983;11:91-97.
161. Bhatt PN, Brooks M, Fox JP. Extent of infection with poliomyelitis virus in household associates of clinical cases as determined serologically and by virus isolation using tissue culture methods. *Am J Hyg.* 1955;61:287-301.
162. Roivainen M, Agboatwalla M, Stenvik M, et al. Intrathecal immune response and virus-specific immunoglobulin M antibodies in laboratory diagnosis of acute poliomyelitis. *J Clin Microbiol.* 1993;31:2427-2432.
163. Wiechers D. Electrophysiology of acute polio revisited: utilizing newer EMG techniques in vaccine-associated disease. *Ann N Y Acad Sci.* 753:111–119, 1995.
164. Malzberg MS, Rogg JM, Tate CA, et al. Poliomyelitis hyperintensity of the anterior horn cells on MR images of the spinal cord. *AJR Am J Roentgenol.* 161:863–865, 1993.
165. Bernstein HG, Clark JM, Tunbridge RE. Acute anterior poliomyelitis among service personnel in Malta: account of epidemic. *Br Med J.* 1:763–767, 1945.
166. Fraser FR. A study of the cerebrospinal fluid in acute poliomyelitis. *J Exp Med.* 18:242–251, 1913.
167. Marx A, Glass J, Sutter RW. Differential diagnoses of acute flaccid paralysis and its role in poliomyelitis surveillance. *Epidemiol Rev.* 22:298–316, 2000.
168. Salisbury DM, Ramsay ME, White JM, et al. Polio eradication: surveillance implications for the United Kingdom. *J Infect Dis.* 175(Suppl 1):S156–S159, 1997.
169. Olive JM, Castillo C, Castro RG, et al. Epidemiologic study of Guillain-Barré syndrome children in <15 years of age in Latin America. *J Infect Dis.* 175(Suppl 1):S160–S164, 1997.
170. Herceg A, Kennett M, Antony J, et al. Acute flaccid paralysis surveillance in Australia: the first year. *Commun Dis Intell.* 20:403–405, 1996.
171. Grist NR, Bell EG. Enteroviral etiology of the paralytic poliomyelitis syndrome. *Arch Environ Health.* 21:382–387, 1970.
172. Voroshilova MK, Chumakov MP. Poliomyelitis-like properties of AB-IV-Coxsackie A7 group of viruses. *Prog Med Virol.* 2:106–170, 1959.
173. Melnick JL. Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. *Rev Infect Dis.* 6(Suppl 2):S387–S390, 1984.
174. Lee BY, Wateska AR, Bailey RR, et al. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. *Vaccine.* 28:7731–7736, 2010.
175. Tee KK, Lam TT-Y, Chan YF, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. *J Virol.* 84:3339–3350, 2010.

- 175a. Greninger AL, Naccache SN, Messacar K, et al. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. *Lancet Infect Dis.* 2015;15:671-682.
176. Dyken P, Krawiecki N. Neurodegenerative diseases in infancy and childhood. *Ann Neurol.* 13:351–364, 1983.
177. Daube JR. Electrophysiologic studies in the diagnosis and prognosis of motor neuron diseases. *Neurol Clin.* 3:473–493, 1985.
178. McKhann GM, Cornbluth DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic diseases of children and young adults in northern China. *Lancet.* 338:593–597, 1991.
179. Weber JT, Hatheway CL, St. Louis ME. Botulism. In: Hoeprich PD, Colin Jordan M, Ronald AR, (eds). *Infectious Diseases: A Treatise of the Infectious Process*, 5th ed Philadelphia, PA: JB Lippincott; 1994. 1185–1194.
180. Hoeprich PD. Diphtheria. In: Hoeprich PD, Colin Jordan M, Ronald AR, (eds). *Infectious Diseases: A Treatise of the Infectious Process*, 5th ed, Philadelphia, PA: JB Lippincott; 1994, 373–380.
181. Sutter RW, Orenstein WA, Wassilak SG. Tetanus. In: Hoeprich PD, Colin Jordan M, Ronald AR, (eds) *Infectious Diseases: A Treatise of the Infectious Process*, 5th ed, Philadelphia, PA: JB Lippincott; 1994, 1175–1185.
182. Leis A, Stokic D, Plok K, et al. Acute flaccid paralysis syndrome associated with West Nile virus infection: Mississippi and Louisiana, July-August 2002. *MMWR Morb Mortal Wkly Rep.* 51:825–828, 2002.
183. Leis AA, Stokic DS, Plok JL, et al. A polio-like syndrome from West Nile virus infection. *N Engl J Med.* 347:1280–1281, 2002.
184. Glass JD, Samuels O, Rich MM. Poliomyelitis due to West Nile Virus. *N Engl J Med.* 347:1281–1282, 2002.
185. Solomon T, Kneen R, Dung NM, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. *Lancet.* 351:1094–1097, 1998.
186. Wyatt HV. Poliomyelitis and infantile paralysis: changes in host and virus. *Hist Philos Life Sci.* 15:357–396, 1993.
187. Paul JR, Riordan JT, Melnick JL. Antibodies to three different antigenic types of poliomyelitis virus in sera of North Alaskan Eskimos. *Am J Hyg.* 54:275–285, 1951.
188. Salk J. Requirements for persisting immunity to poliomyelitis. *Trans Assoc Am Physicians.* 69:105–114, 1956.
189. Shelokov A, Habel K, McKinstry DW. Relation of poliomyelitis virus types to clinical disease and geographic distribution: a preliminary report. *Ann N Y Acad Sci.* 61:998–1004, 1955.
- 189a. Adams A, Salisbury DM. Eradicating polio. *Science.* 2015;350:609.

190. Centers for Disease Control and Prevention. Possible eradication of wild poliovirus type 3—worldwide, 2012. *MMWR Morb Mortal Wkly Rep.* 2014;63:1059-1063.
191. Aycock WL. A milk-borne epidemic of poliomyelitis. *Am J Hyg.* 7:791–803, 1927.
192. Bancroft PM, Engelhard WE, Evans C. Poliomyelitis in Huskerville (Lincoln) Nebraska: studies indicating a relationship between clinically severe infection and proximate fecal pollution of water. *JAMA.* 164:836–847, 1957.
193. Horstmann DM, Paul JR. The incubation period in human poliomyelitis and its implications. *JAMA.* 135:11–14, 1947.
194. Melnick JL, Ledinko N. Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period: the ratio of inapparent infection to clinical poliomyelitis. *Am J Hyg.* 58:207–222, 1953.
195. Penttinen K, Patiala R, Bremer D. The paralytic/infected ratio in a susceptible population during a polio type 1 epidemic. *Ann Med Exp Biol Fenn.* 39:195–202, 1961.
196. Bernier RH. Some observations on poliomyelitis lameness surveys. *Rev Infect Dis.* 6(Suppl 2):S371–S375, 1984.
197. Centers for Disease Control and Prevention. Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. *MMWR Morb Mortal Wkly Rep.* 46:641–643, 1997.
198. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. *J Clin Microbiol.* 36:2893–2899, 1998.
199. Wood D, Sutter RW, Dowdle W. Stopping vaccination following poliomyelitis eradication: issues and challenges. *Bull World Health Organ.* 78:847–857, 2000.
200. MacCallum FO. *The Role of Humoral Antibodies in Protection Against and Recovery From Bacterial and Virus Infections in Hypogammaglobulinemia.* London, England: Medical Research Council; 1971. Medical Research Council Special Report Series, 310.
201. Martín J, Dunn G, Hull R, et al. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of excretion. *J Virol.* 74:3001–3010, 2000.
202. Hara M, Saito Y, Komatsu T, et al. Antigenic analysis of poliovirus isolated from a child with agammaglobulinemia. *Microbiol Immunol.* 25:905–913, 1981.
203. Abo W, Chiba S, Yamanaka T, et al. Paralytic poliomyelitis in a child with agammaglobulinemia. *Eur J Pediatr.* 132:11–16, 1979.
204. Misbah SA, Lawrence PA, Kurtz JB, et al. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinemia. *Postgrad Med J.* 67:301–303, 1991.
205. Bellmunt A, May G, Zell R, et al. Evolution of a poliovirus type 1 during 5.5 years of prolonged enteral replication in an immunodeficient patient. *Virology.* 265:178–184, 1999.

206. MacLennan CA, Dunn G, Wood P, et al. Chronic infection with vaccine-derived neurovirulent poliovirus in a common variable immunodeficiency and implications for world health. *J Allergy Clin Immunol.* 107(Suppl):S304–S305, 2001.
207. Fiore L, Plebani A, Buttinelli G, et al. Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. *Clin Immunol.* 111:98–102, 2004.
208. Taiwan Polio Eradication Certification Committee. National Documentation for Maintenance of Poliomyelitis Eradication in Taiwan for the Period July 2000–December 2001. Taipei: Taiwan Polio Eradication Certification Committee; April 2000.
209. MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. *Lancet.* 363:1509–1513, 2004.
210. Guo J, Bolivar-Wagers S, Srinivas N, et al. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. *Vaccine.* 2015;33(10):1235-1242.
211. McKinlay MA, Collett MS, Hincks JR, et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. *J Infect Dis.* 2014;210:S447-S453.
212. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of poliomyelitis, 1976–1995. *J Infect Dis.* 175(Suppl 1):S165–S172, 1997.
213. Prevots DR, Ciofi M, Sallabanda A, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. *Clin Infect Dis.* 26:419–425, 1998.
214. World Health Organization. Outbreak of poliomyelitis, Cape Verde. *Wkly Epidemiol Rec.* 75:401, 2000.
215. Centers for Disease Control and Prevention. Outbreak of poliomyelitis: Cape Verde, 2000. *MMWR Morb Mortal Wkly Rep.* 49:1070, 2000.
216. Centers for Disease Control and Prevention. Outbreaks following wild poliovirus importations: Europe, Africa, and Asia, January 2009–September 2010. *MMWR Morb Mortal Wkly Rep.* 59:1393–1399, 2010.
217. Grard G, Drexler JF, Lekana-Douki S, et al. Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October–November 2010. *Euro Surveill.* 15, 2010.
218. Mach O, Tangermann RH, Wassilak SG, et al. Outbreaks of paralytic poliomyelitis during 1996–2012: the changing epidemiology of a disease in the final stages of eradication. *J Infect Dis.* 2014;210(Suppl 1):S275-S282.
219. Bradford Hill AB, Knowelden J. Inoculation and poliomyelitis: a statistical investigation in England and Wales in 1949. *Br Med J.* 2:1–6, 1950.

220. Sutter RW, Patriarca PA, Suleiman AJM, et al. Attributable risk of DTP (diphtheria-tetanus toxoids and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman. *J Infect Dis.* 165:444–449, 1992.
221. Lambert SM. A yaws campaign and an epidemic of poliomyelitis in Western Samoa. *J Trop Med Hyg.* 39:41–46, 1936.
222. Korns RF, Albrecht RM, Locke FB. The association of parenteral injections with poliomyelitis. *Am J Public Health.* 42:153–169, 1952.
223. Trueta J, Hodes R. Provoking and localising factors in poliomyelitis: an experimental study. *Lancet.* 1:998–1001, 1954.
224. Horstmann DM. Acute poliomyelitis: relation of physical activity at the time of onset to the course of the disease. *JAMA.* 142:236–241, 1950.
225. Talmey M. Predisposing factors in infantile paralysis. *N Y Med J.* 104:202–204, 1916.
226. Aycock WL. Frequency of poliomyelitis in pregnancy. *N Engl J Med.* 225:405–408, 1941.
227. Nathanson N, Bodian D. Experimental poliomyelitis following intramuscular virus injection, I: the effect of neural block on a neurotropic and a pantropic strain. *Bull Johns Hopkins Hosp.* 108:308–319, 1961.
228. Nathanson N, Bodian D. Experimental poliomyelitis following intramuscular virus injection, II: viremia and the effect of antibody. *Bull Johns Hopkins Hosp.* 108:320–333, 1961.
229. Gromeier M, Solcki D, Patel DD, et al. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. *Virology.* 74:7381–7390, 2000.
230. Ohka S, Yang WX, Terada E, et al. Retrograde transport of intact poliovirus through the axon via the fast transport system. *Virology.* 250:67–75, 1998.
231. Aycock WL. Tonsillectomy and poliomyelitis, I: epidemiological considerations. *Medicine (Baltimore).* 21:65–94, 1942.
232. Sabin AB. Experimental poliomyelitis by the tonsillopharyngeal route with special reference to the influence of tonsillectomy on the development of bulbar paralysis. *JAMA.* 111:605–610, 1938.
233. von Magnus H, Melnick JL. Tonsillectomy in experimental poliomyelitis. *Am J Hyg.* 48:113–125, 1948.
234. Ogra PL. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. *N Engl J Med.* 284:59–64, 1971.
235. Ogra PL, Karzon DT. Formation and function of poliovirus antibody in different tissues. *Prog Med Virol.* 13:156–193, 1971.

236. Bernkopf H, Medalie J, Yekutieli M. Antibodies to poliomyelitis virus and socioeconomic factors influencing their frequency in children in Israel. *Am J Trop Med Hyg.* 1957;697–703, 1957.
237. Pal SR, Banerjee G, Aikat BK. Serological investigation on endemicity of poliomyelitis in Calcutta and in a neighboring rural area. *Indian J Med Res.* 54:507–511, 1966.
238. Sutter RW, Patriarca PA, Suleiman AJ, et al. Paralytic poliomyelitis in Oman: association between regional differences in attack rate and variations in antibody responses to oral poliovirus vaccine. *Int J Epidemiol.* 22: 936–944, 1993.
239. Swartz TA, Skalska P, Gerichter CG, et al. Routine administration of oral polio vaccine in a subtropical area: factors possibly affecting sero-conversion. *J Hyg (Lond).* 70:719–726, 1972.
240. Herndon CN, Jennings RG. A twin-family study of susceptibility to poliomyelitis. *Am J Hum Genet.* 3:17–46, 1951.
241. van Eden W, Persijn GG, Bijerk H, et al. Differential resistance to paralytic poliomyelitis controlled by histocompatibility leukocyte antigens. *J Infect Dis.* 147:422–426, 1983.
242. Wyatt HV. Is poliomyelitis a genetically-determined disease? I: a genetic model. *Med Hypotheses.* 1:35–42, 1975.
243. World Health Organization. Outbreak news: outbreak of poliomyelitis, Republic of the Congo, September 2010–February 2011. *Wkly Epidemiol Rec.* 86:141–142, 2011.
244. Gregory CJ, Ndiaye S, Patel M, et al. Investigation of elevated case-fatality rate in poliomyelitis outbreak in Pointe Noire, Republic of Congo, 2010. *Clin Infect Dis.* 2012;55:1299-1306.
245. Patel MK, Konde MK, Didi-Ngossaki BH, et al. An outbreak of wild poliovirus in the Republic of Congo, 2010-2011. *Clin Infect Dis.* 2012;55:1291-1298.
246. Allmond W, Froeschle JE, Gilloud NB. Paralytic poliomyelitis in large laboratory primates. *Am J Epidemiol.* 85:229–239, 1967.
247. Goodall J. *The Chimpanzees of Gombe.* Boston, MA: Belknap Press; 1986.
248. Ruch TC. *Diseases of Laboratory Primates.* London, England: WB Saunders; 1967.
249. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. *J Infect Dis.* 175(Suppl 1):S286–S292, 1997.
250. Fine PE. Herd immunity: history, theory, practice. *Epidemiol Rev.* 15:265–302, 1993.
251. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis initiative. *Am J Epidemiol.* 150:1001–1021, 1999.
252. Furesz J, Armstrong RE, Contreras G. Viral and epidemiological links between poliomyelitis outbreaks in unprotected communities in Canada and the Netherlands [letter]. *Lancet.* 2:1248, 1978.
253. Schonberger LR, Kaplan J, Kim-Farley R, et al. Control of paralytic poliomyelitis in the United States. *Rev Infect Dis.* 6(Suppl 2):S424–S426, 1984.

254. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. *Rev Infect Dis.* 13:926–939, 1991.
255. Sutter RW, Patriarca PA, Brogan S, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. *Lancet.* 338:715–720, 1991.
256. El-Sayed N, Al-Jorf S, Hennessey K, et al. Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. *Vaccine.* 25:5062–5070, 2007.
257. Bahl S, Estívariz CF, Sutter RW, et al. Cross-sectional serologic assessment of immunity to poliovirus infection in high-risk areas of northern India. *J Infect Dis.* 2014;210(Suppl 1):S243-S251.
258. Melnick JL. Live attenuated poliovirus vaccines. In: Plotkin SA, Mortimer EA, (eds). *Vaccines*, 2nd ed. Philadelphia, PA: WB Saunders; 1994, 155–204.
259. Otten MW, Deming MS, Jaiteh KO, et al. Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease, I: descriptive findings. *Am J Epidemiol.* 135:381–392, 1992.
260. Afif H, Sutter RW, Kew OM, et al. Outbreak of poliomyelitis in Gizan, Saudi Arabia: cocirculation of wild type 1 polioviruses from three separate origins. *J Infect Dis.* 175(Suppl 1):S71–S75, 1997.
261. Reichler MR, Abbas A, Kharabsheh S, et al. Outbreak of paralytic poliomyelitis in a highly immunized population in Jordan. *J Infect Dis.* 175(Suppl 1):S62–S70, 1997.
262. Melnick JL, Benyesh-Melnik M, Pena R, et al. Effectiveness of Salk vaccine: analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis. *JAMA.* 175: 1159–1162, 1961.
263. Bottiger M. Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating poliovirus. *Rev Infect Dis.* 6(Suppl 2):S548–S551, 1984.
264. Lapinleimu K. Elimination of poliomyelitis in Finland. *Rev Infect Dis.* 6(Suppl 2):S456–S460, 1984.
265. Grachev VP. Long-term use of oral poliovirus vaccine from Sabin strains in the Soviet Union. *Rev Infect Dis.* 6(Suppl 2):S321–S322, 1984.
266. Nathanson N. Epidemiologic aspects of poliomyelitis eradication. *Rev Infect Dis.* 6(Suppl 2):S308–S312, 1984.
267. Sabin AB. Oral poliovirus vaccine: recent results and recommendations for optimum use. *R Soc Health J.* 82:51–59, 1962.
268. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. *Clin Infect Dis.* 14:568–579, 1992.

269. Cruz RR. Cuba: mass polio vaccination program. *Rev Infect Dis.* 6(Suppl 2):S408–S412, 1984.
270. Immunization, Vaccines and Biologicals Department. WHO Vaccine-Preventable Diseases Monitoring System. 2006 Global Summary. Geneva, Switzerland: World Health Organization; 2006.
271. Heymann DL, Murphy K, Brigaud M, et al. Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates. *Bull World Health Organ.* 65:495–501, 1987.
272. Risi JB. The control of poliomyelitis in Brazil. *Rev Infect Dis.* 6(Suppl 2):S400–S403, 1984.
273. Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? *Am J Epidemiol.* 143:816–822, 1996.
274. Hatziafreu EJ, Palmer CS, Halpern MT, et al. A Cost Benefit Analysis of OPV: Final Report. Arlington, VA: Battelle; 1994.
275. Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. *Lancet.* 369:1363–1371, 2007.
276. Centers for Disease Control. Summary of notifiable diseases, United States, 1990. *MMWR Morb Mortal Wkly Rep.* 39:1–61, 1991.
277. World Health Organization. Poliomyelitis in 1980, parts 1 and 2. *Wkly Epidemiol Rec.* 56:329–332, 337–341, 1981.
278. World Health Organization (WHO). AFP/Polio Data. Available at: <https://extranet.who.int/polis/public/CaseCount.aspx>
279. Kubli D, Steffen R, Schar M. Importation of poliomyelitis in industrialised nations between 1975 and 1984: evaluation and conclusions for vaccination recommendations. *Br Med J (Clin Res Ed).* 295:169–171, 1987.
280. Oostvogel PM, van Wijngaarden JK, van der Avoort HG, et al. Poliomyelitis in an unvaccinated community in the Netherlands, 1992–1993. *Lancet.* 344:665–670, 1994.
281. Bernal A, Garcia-Saiz A, Liacer A, et al. Poliomyelitis in Spain, 1982–1984: virologic and epidemiologic studies. *Am J Epidemiol.* 126:69–76, 1987.
282. Centers for Disease Control. Poliomyelitis: Pennsylvania, Maryland. *MMWR Morb Mortal Wkly Rep.* 28:49–50, 1979.
283. Aylward RB, Porta D, Fiore L, et al. Unimmunized gypsy populations and implications for the eradication of poliomyelitis in Europe. *J Infect Dis.* 175(Suppl 1):S86–S88, 1997.
284. Balanant JS, Guillot S, Candrea A, et al. The natural genomic variability of poliovirus analyzed by a restriction fragment polymorphism assay. *Virology.* 184:645–654, 1991.
285. Mulders NM, van Loon AM, van der Avoort HG, et al. Molecular characterization of a wild poliovirus type 3 epidemic in the Netherlands (1992 and 1993). *J Clin Microbiol.* 33:3252–3256, 1995.

286. World Health Organization. Poliomyelitis outbreak, Bulgaria. *Wkly Epidemiol Rec.* 67:336–337, 1992.
287. Centers for Disease Control and Prevention. Imported poliovirus causing poliomyelitis: Bulgaria, 2001. *MMWR Morb Mortal Wkly Rep.* 50:1033–1035, 2001.
288. Strebel PM, Aubert-Cambiescu A, Ion-Nedelcu N, et al. Paralytic poliomyelitis in Romania, 1984–1992: evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. *Am J Epidemiol.* 140:1111–1124, 1994.
289. Kew OM, Mulders MN, Lipskaya GY, et al. Molecular epidemiology of polioviruses. *Semin Virol.* 1995;6:401-414.
290. Gavrilin GV, Cherkasova EA, Lipskaya GY, et al. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. *J Virol.* 2000;74:7381-7390.
291. Liu H-M, Zheng D-P, Zhang L-B, et al. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. *J Virol.* 2000;74:11153-11161.
292. Jenkins GM, Rambaut A, Pybus OG, et al. Rates of molecular evolution in RNA viruses: a quantitative phylogenetic analysis. *J Mol Evol.* 2002;54:156-165.
293. Martín J, Odoom K, Tuite G, et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. *J Virol.* 2004;78:13839-13847.
294. Yang C-F, Chen H-Y, Jorba J, et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. *J Virol.* 2005;79:12623-12634.
295. Shahmahmoodi S, Parvaneh N, Burns C, et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. *Virus Res.* 2008;137:168-172.
296. Al-Hello H, Jorba J, Blomqvist S, et al. Highly divergent types 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia. *J Virol.* 2013;87:13076-13080.
297. Gavrilin GV, Cherkasova EA, Lipskaya GY, et al. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. *J Virol.* 2000;74:7381-7390.
298. Alexander JP Jr, Zubair M, Khan M, et al. Progress and peril: poliomyelitis eradication efforts in Pakistan, 1994-2013. *J Infect Dis.* 2014;210 Suppl 1:S152-S161.
299. Kew OM, Pallansch MA. The mechanism of polio eradication. In: Semler BL, Wimmer E, eds. *Molecular Biology of Picornaviruses.* Washington, DC: ASM Press; 2002:481-491.
300. Kew O. Reaching the last one per cent: progress and challenges in global polio eradication. *Curr Opin Virol.* 2012;2:188-198.

301. Mulders MN, Lipskaya GY, van der Avoort HG, Ket al. Molecular epidemiology of wild poliovirus type 1 in Europe, the Middle East, and the Indian Subcontinent. *J Infect Dis.* 1995;171:1399-1405.
302. Centers for Disease Control and Prevention. Wild poliovirus importations—West and Central Africa, January 2003–March 2004. *MMWR Morb Mortal Wkly Rep.* 2004;53:433-435.
303. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation—21 countries, 2002–2005. *MMWR Morb Mortal Wkly Rep.* 2006;55:145-150.
304. Centers for Disease Control and Prevention. Outbreaks following wild poliovirus importations—Europe, Africa, and Asia, January 2009–September 2010. *MMWR Morb Mortal Wkly Rep.* 2010;59:1393-1399.
305. Mach O, Tangermann RH, Wassilak SG, et al. Outbreaks of paralytic poliomyelitis during 1996-2012: the changing epidemiology of a disease in the final stages of eradication. *J Infect Dis.* 2014;210 Suppl 1:S275-S282.
306. Gumedde N, Jorba J, Deshpande J, et al. Phylogeny of imported and re-established wild polioviruses in the Democratic Republic of Congo from 2006 to 2011. *J Infect Dis.* 2014;210:S361-S367.
307. Estívariz C, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island—Indonesia, 2005. *J Infect Dis.* 2008;197:347-354.
308. World Health Organization. Progress towards eradicating poliomyelitis: Afghanistan and Pakistan, January 2011–August 2012. *Wkly Epidemiol Rec.* 2012;87:381-388.
309. World Health Organization. Progress towards poliomyelitis eradication, Nigeria, January 2011–September 2012. *Wkly Epidemiol Rec.* 2012;87:439-446.
310. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar. *Emerg Infect Dis.* 2003;9:885-887.
311. Shimizu H, Thorley B, Paladin FJ, et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. *J Virol.* 2004;78:13512-13521.
312. Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an under-vaccinated community—Minnesota, USA. *J Infect Dis.* 2009;199:391-397.
313. Yan D, Li L, Zhu S, et al. Emergence and localized circulation of a vaccine-derived poliovirus in an isolated mountain community in Guangxi, China. *J Clin Microbiol.* 2010;48:3274-3280.
314. World Health Organization. Progress towards poliomyelitis eradication in Egypt, 2001. *Wkly Epidemiol Rec.* 2002;77:70-74.
315. Netter A. Sérothérapie de la poliomyélite: nos résultats chez 30 malades: indications, techniques, incidents possibles. *Bull Acad Med.* 74:403–423, 1915.

316. Paul JR. Convalescent serum therapy. In: *A History of Poliomyelitis*. New Haven, CT: Yale University Press; 1971, 190–199.
317. Flexner S, Lewis PA. Experimental poliomyelitis in monkeys: active immunization and passive protection. *JAMA*. 54:1780–1782, 1910.
318. Gelfand HM, Fox JP, LeBlanc DR, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana, V: passive transfer of polio antibody from mother to fetus, and natural decline and disappearance of antibody in the infant. *J Immunol*. 85:46–55, 1960.
319. Hammon WM, Coriell LL, Wehrle PF. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis, IV: final report of results based on clinical diagnosis. *JAMA*. 151:1272–1285, 1953.
320. National Advisory Committee for the Evaluation of Gamma Globulin in the Prophylaxis of Poliomyelitis. *An Evaluation of the Efficacy of Gamma Globulin in the Prophylaxis of Paralytic Poliomyelitis as Used in the United States 1953*. Washington, DC: US Public Health Service; 1954. Publication 358.
321. Department of Drugs. *Drug Evaluations Annual 1991*. Milwaukee, WI: American Medical Association; 1991.
322. O’Neal KM, Pallansch MA, Winkelstein JA, et al. Chronic group A coxsackievirus infection in agammaglobulinemia: demonstration of genomic variation of serotypically identical isolates persistently excreted by the same patient. *J Infect Dis*. 157:183–186, 1988.
323. Davis LE, Bodian D, Price D, et al. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. *N Engl J Med*. 297:214–245, 1977.
324. Romer PH. *Die epidemische Kinderlähmung (Heine-Medinsche Krankheit)*. Berlin, Germany: Springer; 1911.
325. Brodie M, Goldblum A. Active immunization against poliomyelitis in monkeys. *J Exp Med*. 53:885–893, 1931.
326. Brodie M. Active immunization against poliomyelitis. *J Exp Med*. 56:493–505, 1932.
327. Brodie M, Park WH. Active immunization against poliomyelitis. *N Y State J Med*. 35: 815–818, 1935.
328. Brodie M, Park WH. Active immunization against poliomyelitis. *JAMA*. 105:1089–1093, 1935.
329. Kolmer JA. Susceptibility and immunity in relation to vaccination in acute anterior poliomyelitis. *JAMA*. 105: 1956–1963, 1935.
330. Leake JP. Poliomyelitis following vaccination against this disease. *JAMA*. 105:2152, 1936.
331. Koprowski H, Jervis GA, Norton TW. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. *Am J Hyg*. 55:108–126, 1952.
332. Li CP, Schaeffer M, Nelson DB. Experimentally produced variants of poliomyelitis virus combining in vivo and in vitro techniques. *Ann N Y Acad Sci*. 61:902–910, 1955.

333. Melnick JL. Variation in poliomyelitis virus on serial passage through tissue culture. *Cold Spring Harb Symp Quant Biol.* 18:178–179, 1953.
334. Sabin AB, Hennessen WA, Winsser J. Studies on variants of poliomyelitis virus, I: experimental segregation and properties of avirulent variants of three immunologic types. *J Exp Med.* 99:551–576, 1954.
335. Poliomyelitis: Papers and Discussions Presented at the 4th International Poliomyelitis Conference. Philadelphia, PA: JB Lippincott; 1958.
336. Poliomyelitis: Papers and Discussions Presented at the 5th International Poliomyelitis Conference. Philadelphia, PA: JB Lippincott; 1961.
337. Pan American Health Organization. Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960.
338. Pan American Sanitary Bureau. Proceedings of the First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959.
339. Sabin AB. Present position of immunization against poliomyelitis with live virus vaccines. *Br Med J.* 1:663–680, 1959.
340. Koprowski H. Live poliomyelitis virus vaccines: present status and problems for the future. *JAMA.* 178:1151–1155, 1961.
341. Paul JR. Status of vaccination against poliomyelitis, with particular reference to oral vaccination. *N Engl J Med.* 264:651–658, 1961.
342. Koprowski H. The 10th anniversary of the development of live poliovirus vaccine. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960.
343. Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. *JAMA.* 164:1216–1223, 1957.
344. Melnick JL. Problems associated with the use of live poliovirus vaccine. *Am J Public Health.* 50:1013–1031, 1960.
345. Melnick JL. Tests for safety of live poliovirus vaccine. *Bull Acad Med N J.* 6:146–167, 1960.
346. Melnick JL, Benyesh-Melnick M, Brennan JC. Studies on live poliovirus vaccine: its neurotropic activity in monkeys and its increased neurovirulence after multiplication in vaccinated children. *JAMA.* 171:1165–1172, 1959.
347. Melnick JL. Attenuation of poliomyelitis viruses on passage through tissue culture. *Fed Proc.* 13:505, 1954.
348. Murray R, Kirschstein R, van Hoosier G, et al. Comparative virulence for rhesus monkeys of poliovirus strains used for oral administration. In: Proceedings of the First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959, 39–64.

349. Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. *J Virol.* 63:1338–1344, 1989.
350. Macadam AJ, Stone DM, Almond JW, et al. The 5′ noncoding region and virulence of poliovirus vaccine strains. *Trends Microbiol.* 1994;2:449-454.
351. Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in type 1 poliovirus Sabin strain. *J Virol.* 69:4972–4978, 1995.
352. Ren R, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. *J Virol.* 65:1377–1382, 1991.
353. Macadam AJ, Arnold C, Howlett J, et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain poliovirus in vaccinees. *Virology.* 172:408–414, 1989.
354. Tatem J, Weeks-Levy C, Georgiu A, et al. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. *J Virol.* 66:3194–3197, 1992.
355. Nomoto A, Omata T, Toyoda H, et al. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. *Proc Natl Acad Sci U S A.* 1982;79:5793-5797.
356. Omata T, Kohara M, Kuge S, et al. Genetic analysis of the attenuation phenotype of poliovirus type 1. *J Virol.* 1986;58:348-358.
357. Kawamura N, Kohara M, Abe S, et al. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. *J Virol.* 1989;63:1302-1309.
358. Paul AV, Mugavero J, Yin J, et al. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. *Virology.* 2000;272:72-84.
359. Christodoulou C, Colbere-Garapin F, Macadam A, et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. *J Virol.* 1990;64:4922-4929.
360. Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. *Virology.* 1993;192:18-26.
361. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. *J Biol Stand.* 1973;1:115-118.
362. Stanway G, Hughes PJ, Mountford RC, et al. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. *Proc Natl Acad Sci U S A.* 1984;81:1539-1543.
363. Minor PD. The molecular biology of poliovaccines. *J Gen Virol.* 1992;73:3065-3077.
364. Rowe A, Ferguson GL, Minor PD, et al. Coding changes in the poliovirus protease 2A compensate for 5′ NCR domain V disruptions in a cell-specific manner. *Virology.* 2000;269:284-293.

365. Macadam A, Ferguson G, Arnold C, et al. An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. *J Virol.* 1991;65:5225-5231.
366. Tardy-Panit M, Blondel B, Martin A, et al. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. *J Virol.* 1993;67:4630-4638.
367. Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. *J Infect Dis.* 2014;210:S380-S389.
368. Martín J, Minor PD. Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. *J Virol.* 2002;76:5339-5349.
369. Kitamura N, Semler BL, Rothberg PG, et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. *Nature.* 1981;291:547-553.
370. Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. *Proc Natl Acad Sci U S A.* 1981;78:4887-4891.
371. Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. *Science.* 1981;214:916-919.
372. Muzychenko AR, Lipskaya GY, Maslova SV, et al. Coupled mutations in the 5' untranslated region of the Sabin poliovirus strains during in vivo passage: structural and functional implications. *Virus Res.* 1991;21:111-122.
373. Haller AA, Stewart SR, Semler BL. Attenuation stem-loop lesions in the 5' noncoding region of poliovirus RNA: neuronal cell-specific translation defects. *J Virol.* 1996;70:1467-1474.
374. Gromeier M, Bossert B, Arita M, et al. Dual stem loops within the poliovirus internal ribosome entry site controls neurovirulence. *J Virol.* 1999;73:958-964.
375. Minor PD, Dunn G. The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut. *J Gen Virol.* 1988;69:1091-1096.
376. Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. *Proc Natl Acad Sci U S A.* 1996;93:2370-2375.
377. Svitkin YV, Pestova T, Maslova SV, et al. Point mutations modify the response of poliovirus RNA to a translation initiation factor: a comparison of neurovirulent and attenuated strains. *Virology.* 1988;166:394-404.
378. Svitkin Y, Cammack N, Minor PD, et al. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472-U. *Virology.* 1990;175:103-109.
379. Agol VI, Drozdov SG, Ivannikova TA, et al. Restricted growth of attenuated poliovirus strains in cultured cells of a human neuroblastoma. *J Virol.* 1989;63:4034-4038.

380. La Monica N, Racaniello VR. Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. *J Virol.* 1989;63:2357-2360.
381. Gutiérrez AL, Denova-Ocampo M, Racaniello VR, et al. Attenuating mutations in the poliovirus 5' untranslated region alter its interaction with polypyrimidine tract-binding protein. *J Virol.* 1997;71:3826-3833.
382. Guest S, Pilipenko E, Sharma K, et al. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. *J Virol.* 2004;78:11097-11107.
383. Kauder SE, Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. *J Clin Invest.* 2004;113:1743-1753.
384. Payne AM. Field safety and efficacy of live attenuated poliovirus vaccines. *Poliomyelitis Papers and Discussion Presented at the Fifth International Poliomyelitis Conference.* Philadelphia, PA: J.B. Lippincott; 1961:257-261.
385. Centers for Disease Control and Prevention. Wild poliovirus type 1 and type 3 importations—15 countries, Africa, 2008–2009. *MMWR Morb Mortal Wkly Rep.* 2009;58:357-362.
386. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. *Am J Epidemiol.* 1979;110:672-692.
387. Chumakov KM, Norwood LP, Parker ML, et al. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. *J Virol.* 1992;66:966-970.
388. Sutter RW, Cáceres VM, Más Lago P. The role of routine polio immunization in the post-certification era. *Bull World Health Organ.* 2004;82:31-39.
389. Horwitz A, Martins da Silva M, Bica AN. Large-scale field studies with live attenuated polioviruses in the Americas. In: *Proceedings of the Fifth International Poliomyelitis Conference.* Philadelphia, PA: JB Lippincott; 1961, 221–227.
390. Cox HR, Cabasso VJ, Markham FS, et al. Immunologic response to trivalent oral poliomyelitis vaccine. In: *Proceedings of the First International Conference on Live Poliovirus Vaccines.* Washington, DC: Pan American Sanitary Bureau, 1959, 229–248.
391. Voroshilova MK. Influence of dose and schedule of oral immunization of people with live poliovirus vaccine on antibody response. In: *Proceedings of the Fifth International Poliomyelitis Conference.* Philadelphia, PA: JB Lippincott; 1961, 296–303.
392. Verlinde JD, Wilterdink JB. A small-scale trial on vaccination and revaccination with live attenuated polioviruses in The Netherlands. In: *Proceedings of the First International Conference on Live Poliovirus Vaccines.* Washington, DC: Pan American Sanitary Bureau, 1959, 355–366.
393. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. *Clin Infect Dis.* 33:531–541, 2001.

394. Embil J, Gervais L, Hernandez Miyares C, et al. Use of attenuated live poliovirus vaccine in Cuban children. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960, 365–370.
395. Kimball AC, Barr RN, Bauer H, et al. Minnesota studies with oral poliomyelitis vaccine: community spread of orally administered attenuated poliovirus vaccine strains. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960, 161–173.
396. Krugman S, Warren J, Eiger MS, et al. Immunization of newborn infants with live attenuated poliovirus vaccine. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960, 315–321.
397. Paul JR, Horstmann DM, Riordan JT, et al. The capacity of live attenuated polioviruses to cause human infection and to spread within families. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960, 174–184.
398. Tomlinson AJ, Davies J. Trial of live attenuated poliovirus vaccine: a report to the Public Health Laboratory Service from the Poliomyelitis Vaccines Committee of the Medical Research Council. *Br Med J.* 2:1037–1044, 1961.
399. Voroshilova MK, Zhevandrova VI, Tolskaya EA, et al. Virologic and serologic investigations of children immunized with trivalent live vaccine from A. B. Sabin’s strains. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960, 240–265.
400. Zhdanov VM, Chumakov MP, Smorodintsev AA. Large-scale practical trials and use of live poliovirus vaccine in the USSR. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960, 576–588.
401. Ramos Alvarez M, Gomez Santos F, Rivera LR, et al. Viral and serological studies in children immunized with live poliovirus vaccine: preliminary report of a large trial conducted in Mexico. In: Proceedings of the First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959, 483–494.
402. Ramos Alvarez M, Bustamante ME, Alvarez Alba R. Use of Sabin’s live poliovirus vaccine in Mexico: results of a large-scale trial. In: Proceedings of the Second International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1960, 386–409.
403. Robertson HE, Acker MS, Dillenberg HO, et al. Community-wide use of a “balanced” trivalent oral poliovirus vaccine (Sabin): a report of the 1961 trial at Prince Albert. Saskatchewan. *Can J Public Health.* 53:179–191, 1962.
404. U.S. Food and Drug Administration. Additional standards for viral vaccines: poliovirus vaccine live oral: final rule (21 CFR Part 630). *Fed Regist.* 56:21418–21438, 1991.

405. Public Health Service. Public Health Service Regulations: Biological Products. Title 42, Part 73. Washington, DC: US Department of Health, Education and Welfare; 1967.
406. Patriarca PA, Laender F, Palmeira G, et al. Randomised trial of alternative formulations of oral poliovaccine in Brazil. *Lancet*. 1:429–433, 1988.
407. World Health Organization. Report of the 13th Global Advisory Group Meeting, Cairo, 14–18 October 1990. Geneva, Switzerland: World Health Organization; 1991.
408. Poliovirus Vaccine Live Oral Trivalent [package insert]. Pearl River, NY: Lederle Laboratories; 1993.
409. Global Programme for Vaccines and Immunization. International List of Availability of Vaccines and Sera. Geneva, Switzerland: World Health Organization; 1995.
410. Kew OM, Nottay BK. Molecular epidemiology of polioviruses. *Rev Infect Dis*. 6(Suppl 2):S499–S504, 1984.
411. Domok I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959–1982. *Rev Infect Dis*. 6(Suppl 2):S413–S418, 1984.
412. Schoub BD, Johnson S, McAnererney J, et al. Monovalent neonatal polio immunization: a strategy for the developing world. *J Infect Dis*. 157:836–839, 1988.
413. World Health Organization. Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21–22 September 2004. *Wkly Epidemiol Rec*. 79:401–407, 2004.
414. Cochi SL, Sutter RW, Kew OM, et al. Decision tree for stopping polio immunization. Presented at: Technical Consultation on the Global Eradication of Poliomyelitis. Geneva, Switzerland; April 28–29, 1997.
415. Cochi SL, Sutter RW, Kew OM, et al. Possible strategies for stopping polio immunization. In: Expanded Programme on Immunization, Global Programme for Vaccines and Immunization, Global Eradication of Poliomyelitis. Report of the Meeting on the Scientific Basis for Stopping Polio Immunization. Geneva, Switzerland: World Health Organization; 1998.
416. Cochi SL, Sutter RW, Kew OM, et al. Possible global strategies for stopping polio immunization and how they could be harmonized. *Dev Biol (Basel)*. 105:153–158, 2001.
417. World Health Organization. Requirements for Poliomyelitis Vaccine (Oral). Requirements for Biological Substances No. 7 (Revised 1989). Geneva, Switzerland: World Health Organization; 1990.
418. Wallis C, Melnick JL. Stabilization of poliovirus by cations. *Tex Rep Biol Med*. 19:683–700, 1961.
419. Petersen I, von Magnus H. Polio neutralization tests with MgCl₂-stabilized virus. *Acta Pathol Microbiol Scand*. 61:652–653, 1964.
420. Yofe J, Goldblum N, Eylan E, et al. An outbreak of poliomyelitis in Israel in 1961 and the use of attenuated type 1 vaccine in its control. *Am J Hyg*. 76:225–238, 1962.

421. Mirchamsy H, Shafyi A, Mahinpour M, et al. Stabilizing effect of magnesium chloride and sucrose on Sabin live polio vaccine. *Dev Biol Stand.* 41:255–257, 1978.
422. Milstien JB, Lemon SM, Wright PF. Development of a more thermostable poliovirus vaccine. *J Infect Dis.* 175(Suppl 1): S247–S253, 1997.
423. Expanded Programme on Immunization. *The Vaccine Vial Monitor.* Geneva, Switzerland: World Health Organization; 1994.
424. WHO Expert Committee on Biological Standardization. WHO Technical Report Series No. 980. Sixty-third Report. Annex 2. Recommendations to assure the quality, safety, and efficacy of poliomyelitis vaccines (oral, live, attenuated). Replacement of Annex 1 of the WHO Technical Report Series, No. 904, and Addendum to Annex 1 of WHO Technical Report Series, No. 910. Geneva, Switzerland: World Health Organization, 2014.
425. Ghendon YUZ, Sanakoyeva II. Comparison of resistance of the intestinal tract to poliomyelitis vaccine (Sabin's strains) in persons after naturally and experimentally acquired immunity. *Acta Virol.* 5:265–273, 1961.
426. Vonka V, Janda Z, Simon J, et al. A new type 3 attenuated poliovirus for possible use in oral poliovirus vaccine. *Prog Med Virol.* 9:204–255, 1967.
427. Melnick JL, Berencsi G, Biberi-Moroeanu S, et al. WHO collaborative studies on poliovirus type 3 strains isolated during the 1968 poliomyelitis epidemic in Poland. *Bull World Health Organ.* 47:287–294, 1972.
428. Kew OM, De L, Yang CF, et al. The role of virologic surveillance in the global initiative to eradicate poliomyelitis. In: Kurstak E, (ed) *Control of Virus Diseases*, New York, NY: Marcel Dekker; 1993, 215–246.
429. Martin J, Ferguson GL, Wood DJ, et al. The vaccine origin of the 1968 epidemic of the type 3 poliomyelitis in Poland. *Virology.* 278:42–49, 2000.
430. Nathanson N, Horn SD. Neurovirulence tests of type 3 poliovirus vaccine manufactured by Lederle Laboratories, 1964–1988. *Vaccine.* 10:469–474, 1992.
431. Poliovirus attenuation: molecular mechanisms and practical aspects. Proceedings of a workshop. Bethesda, Maryland, December 9-10, 1991. *Dev Biol Stand.* 78:1–187, 1993.
432. Sanjuán R, Nebot MR, Chirico N, et al. Viral mutation rates. *J Virol.* 2010;84:9733-9748.
433. Smith EC, Sexton NR, Denison MR. Thinking outside the triangle: replication fidelity of the largest RNA viruses. *Annu Rev Virol.* 2014;1:111-132.
434. Drake JW, Holland JJ. Mutation rates among RNA viruses. *Proc Natl Acad Sci U S A.* 1999;96:13910-13913.
435. Arnold JJ, Cameron CE. Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg²⁺. *Biochemistry.* 2004;43:5126-5137.
436. Domingo E, Sheldon J, Perales C. Viral quasispecies evolution. *Microbiol Mol Biol Rev.* 2012;76:159-216.

437. Vignuzzi M, Stone JK, Arnold JJ, et al. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. *Nature*. 2006;439:344-348.
438. Acevedo A, Brodsky L, Andino R. Mutational and fitness landscapes of an RNA virus revealed through population sequencing. *Nature*. 2014;505:686-690.
439. Neverov A, Chumakov K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. *Proc Natl Acad Sci U S A*. 2010;107:20063-20068.
440. Chumakov KM, Dragunsky EM, Norwood LP, et al. Consistent selection of mutations in 5' untranslated region of oral poliovirus vaccine upon passaging in vitro. *J Med Virol*. 1994;42:79-85.
441. Nomoto A. Recombinant polioviruses as candidates for oral live poliovaccines. *Microbiol Immunol*. 1993;37:169-174.
442. Chumakov KM. PCR engineering of viral quasispecies: a new method to preserve and manipulate genetic diversity of RNA virus populations. *J Virol*. 1996;70:7331-7334.
443. Macadam AJ, Ferguson G, Stone DM, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. *J Virol*. 2006;80:8653-8663.
444. Burns CC, Shaw J, Campagnoli R, et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. *J Virol*. 2006;80:3259-3272.
445. Mueller S, Papamichail D, Coleman JR, et al. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. *J Virol*. 2006;80:9687-9696.
446. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. *Nat Biotechnol*. 2010;28:573-579.
447. Henderson DA, Witte JJ, Morris L, et al. Paralytic disease associated with oral polio vaccines. *JAMA*. 1964;190:41-48.
448. Kohara M, Abe S, Komatsu T, et al. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain. *J Virol*. 1988;62:2828-2835.
449. Iizuka N, Kohara M, Hagino-Yamagishi K, et al. Construction of less neurovirulent polioviruses by introducing deletions into the 5' noncoding region of the genome. *J Virol*. 1989;63:5354-5363.
450. Agol VI, Pilipenko EV, Slobodskaya OR. Modification of translational control elements as a new approach to design of attenuated picornavirus strains. *J Biotechnol*. 1996;44:119-128.
451. Macadam AJ, Ferguson G, Stone DM, et al. Live-attenuated strains of improved genetic stability. *Dev Biol (Basel)*. 2001;105:179-187.

452. Burns CC, Diop OM, Sutter RW, et al. Vaccine-derived polioviruses. *J Infect Dis.* 2014;210:S283-S293.
453. Yin J, Paul AV, Wimmer E, et al. Functional dissection of a poliovirus cis-acting replication element [PV-cre(2C)]: analysis of single- and dual-cre viral genomes and proteins that bind specifically to PV-cre RNA. *J Virol.* 2003;77:5152-5166.
454. Coleman JR, Papamichail D, Skiena S, et al. Virus attenuation by genome-scale changes in codon pair bias. *Science.* 2008;320:1784-1787.
455. Burns CC, Campagnoli R, Shaw J, et al. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. *J Virol.* 2009;83:9957-9969.
456. Pfeiffer JK, Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. *PLoS Pathog.* 2005;1:e11.
457. Sabin AB. Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus. *J Exp Med.* 96: 99–106, 1956.
458. Hammon WM, Ludwig EH. Possible protective effect of previous type 2 infection against paralytic poliomyelitis due to type 1 virus. *Am J Hyg.* 66:274–280, 1957.
459. Bogger-Goren S, Baba K, Hurly P, et al. Antibody response to varicella-zoster virus after natural and vaccine-induced infection. *J Infect Dis.* 146:260–265, 1982.
460. Horstmann DM, Opton EM, Klemperer R, et al. Viremia in infants vaccinated with oral poliovirus vaccine (Sabin). *Am J Hyg.* 79:47–63, 1964.
461. Melnick JL, Proctor RO, Ocampo AR, et al. Free and bound virus in serum after administration of oral poliovirus vaccine. *Am J Epidemiol.* 84: 329–342, 1966.
462. Benyesh-Melnick M, Melnick JL, Rawls WE, et al. Studies on the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. *Am J Epidemiol.* 86:112–136, 1967.
463. McBean AM, Thoms ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. *Am J Epidemiol.* 128:615–628, 1988.
464. Hodes HL, Berger R, Ainbender E, et al. Study of viral antibodies by the paper-reactive virus method. *Pediatrics.* 37:7–18, 1966.
465. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Response to an Infant Immunization Schedule Combining Oral and Inactivated Poliovirus Vaccines Compared With Either Vaccine Alone: Results of a Randomized Trial in The Gambia, Oman, and Thailand. Final Report. Geneva, Switzerland: World Health Organization; 1995.
466. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. *J Infect Dis.* 175(Suppl 1):S215–S227, 1997.

467. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and The Gambia. *J Infect Dis.* 171:1097–1106, 1995.
468. Posey DL, Linkins RW, Oliveria MJ, et al. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. *J Infect Dis.* 175(Suppl 1):S258–S263, 1997.
469. Habib MA, Soofi S, Sheraz A, et al. Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial. *Vaccine.* 2015;33:819-825.
470. Chandir S, Ahamed KU, Baqui AH, et al. Effect of buffer on the immune response to trivalent oral poliovirus vaccine in Bangladesh: a community based randomized controlled trial. *J Infect Dis.* 2014;210(Suppl 1):S373-S379.
471. Saleem AF, Mach O, Quadri F, et al. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan. *Vaccine.* 2015;33:2757-2763.
472. Zaman S, Carlsson B, Morikawa A, et al. Poliovirus antibody titres, relative affinity, and neutralizing capacity in maternal milk. *Arch Dis Child.* 68:198–201, 1993.
473. Ogra SS, Weintraub DI, Ogra PL. Immunologic aspects of human colostrum and milk: interaction with the intestinal immunity of the neonate. *Adv Exp Med Biol.* 107:95–107, 1978.
474. Palmer EL, Gary GW, Black R, et al. Antiviral activity of colostrum and serum immunoglobulins A and G. *J Med Virol.* 5:123–129, 1980.
475. Patriarca PA, Linkins RW, Sutter RW. Poliovirus vaccine formulations. In: Kurstak E, (ed). *Measles and Poliomyelitis: Vaccine, Immunization, and Control*, Vienna, Austria: Springer-Verlag; 1993, 265–277.
476. Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. *Lancet.* 369:1356–1362, 2007.
477. World Health Organization. Polio eradication: surveys of routine immunization coverage and seroprevalence against polioviruses, Yogyakarta Province, Indonesia. *Wkly Epidemiol Rec.* 83:45–48, 2008.
478. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. *Lancet.* 376:1682–1688, 2010.
479. Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. *MMWR Morb Mortal Wkly Rep.* 50:222–224, 2001.
480. World Health Organization. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. *Wkly Epidemiol Rec.* 84:289–290, 2009.
481. Estivariz CF, Anand A, Gary HE, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses

- in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. *Lancet Infect Dis.* 2015;15:898-904.
482. Buisman AM, Abbink F, Schepp RM, et al. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. *J Infect Dis.* 197:698–706, 2008.
483. Grassly NC, Jafari H, Bahl S, et al. Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. *J Infect Dis.* 201:1535–1543, 2010.
484. Sutter RW, Patriarca PA. Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. In: Kurstak E, (ed). *Measles and Poliomyelitis: Vaccines, Immunization and Control*, Vienna, Austria: Springer-Verlag; 1993, 279–294.
485. Smorodintsev AA, Davidenkova EF, Drobyshevskaya AI, et al. Results of a study of the reactogenic and immunogenic properties of live antipoliomyelitis vaccine. *Bull World Health Organ.* 20:1053–1074, 1959.
486. Nishio O, Ishihara Y, Sakae K, et al. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. *J Biol Stand.* 12:1–10, 1984.
487. Janda Z, Adam E, Vonka V. Properties of a new type 3 attenuated poliovirus, VI: alimentary tract resistance in children fed previously with type 3 Sabin vaccine to reinfection with homologous and heterologous type 3 attenuated poliovirus. *Arch Gesamte Virusforsch.* 20:87–98, 1967.
488. Soloviev VD. Problems connected with live polio vaccine. *Proceedings of the Fifth International Poliomyelitis Conference.* Philadelphia, PA: JB Lippincott; 1961, 403–410.
489. Rossen RD, Kasel JA, Couch RB. The secretory immune system: its relation to respiratory viral infections. *Prog Med Virol.* 13:194–238, 1971.
490. Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. *J Infect Dis.* 163:1–6, 1991.
491. Jafari H, Deshpande JM, Sutter RW, et al. Efficacy of inactivated poliovirus vaccine in India. *Science.* 2014;345:922-925.
492. Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. *Rev Infect Dis.* 2:352–369, 1980.
493. Global Programme for Vaccines and Immunization. Report of the Second Meeting of the Global Commission for the Certification of the Eradication of Poliomyelitis, Geneva, 1 May 1997. Geneva, Switzerland: World Health Organization; 1998..
494. Smith JWG, Lee JA, Fletcher WB, et al. The response of oral poliovaccine in persons aged 16–18 years. *J Hyg (Lond).* 76:235–247, 1976.
495. Grassly NC, Jafari H, Bahl S, et al. Waning intestinal immunity following vaccination with oral poliovirus vaccines in India. *J Infect Dis.* 2012;205:1554-61.

496. Ogra PL. Distribution of echovirus antibody in serum, nasopharynx, rectum and spinal fluid after natural infection with echovirus type 6. *Infect Immun.* 2:150–155, 1970.
497. Rovainen M, Hovi T. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin. *J Virol.* 62:3536–3539, 1988.
498. Agol VI, Drozdov SG. Russian contribution to OPV. *Biologicals.* 21:321–325, 1993.
499. Sabin AB. Role of my cooperation with Soviet scientists in the elimination of polio: possible lessons for relations between the USA and the USSR. *Perspect Biol Med.* 31:57–64, 1987.
500. Chumakov MP, Voroshilova MK, Drozdov SG, et al. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. *Bull World Health Organ.* 25:79–91, 1961.
501. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication: the Americas, 1994. *MMWR Morb Mortal Wkly Rep.* 43:720–722, 1994.
502. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication: Western Pacific Region, October 2000. *MMWR Morb Mortal Wkly Rep.* 50:1–3, 2001.
503. World Health Organization. Certification of poliomyelitis eradication, European region, June 2002. *Wkly Epidemiol Rec.* 77:221–223, 2002.
504. Bahl S, Kumar R, Menabde N, et al. Polio-free certification and lessons learned—South-East Asia Region, March 2014. *MMWR Morb Mortal Wkly Rep.* 2014;63:941-946.
505. Hale JH, Doraisingham M, Kanagaratnam K, et al. Large-scale use of Sabin type 2 attenuated poliovirus vaccine in Singapore during a type 1 poliomyelitis epidemic. *Br Med J.* 1:1537–1549, 1959.
506. Knowelden J, Hale JH, Gardner PS, et al. Measurement of the protective effect of attenuated poliovirus vaccine. *Br Med J.* 1:1418–1420, 1961.
507. Fox JP, Gelfand HM, LeBlanc DR, et al. The influence of natural and artificially induced immunity on alimentary infections with polioviruses. *Am J Public Health.* 48:1181–1192, 1958.
508. Koprowski H, Norton TW, Jervis GA, et al. Clinical investigations of attenuated strains of poliomyelitis virus: use as a method of immunization of children with living virus. *JAMA.* 160:954–966, 1956.
509. Paul JR, Horstmann DM, Niederman JC. Immunity in poliomyelitis infection: observations in experimental epidemiology. In: Najjar VA, (ed). *Immunity and Virus Infection.* New York, NY: John Wiley; 1959, 233–245.
510. Skovranek V, Zacek K. Oral poliovirus vaccine (Sabin) in Czechoslovakia: effectiveness of nationwide use in 1960. *JAMA.* 176:524–526, 1961.
511. Plotkin SA, Koprowski H. Epidemiological studies on the safety and efficacy of vaccination with the CHAT strain of attenuated poliovirus in Leopoldville, Belgian Congo. In:

Proceedings of the First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Sanitary Bureau, 1959, 419–436.

512. Rangelova SM. Control of poliomyelitis in Bulgaria: experiences of two decades. *Prog Med Virol.* 31:183–211, 1984.
513. Dong DX. Immunization with oral poliovirus vaccine in China. *Prog Med Virol.* 31:168–182, 1984.
514. Deming MS, Jaiteh KO, Otten MW, et al. Epidemic poliomyelitis in The Gambia following the control of poliomyelitis as an endemic disease, II: clinical efficacy of trivalent oral polio vaccine. *Am J Epidemiol.* 135:393–408, 1992.
515. Horstmann DM, Emmons J, Gimpel L, et al. Enterovirus surveillance following a community-wide oral poliovirus vaccination program: a seven-year study. *Am J Epidemiol.* 97:173–186, 1973.
516. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine: effect of rapid mass immunization on population under conditions of massive enteric infections with other viruses. *JAMA.* 173:1521–1526, 1960.
517. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children: implications for vaccination policy in the United States. *JAMA.* 275:1639–1645, 1996.
518. Ramsay ME, Begg NT, Ghandi J, et al. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. *Pediatr Infect Dis J.* 13:1117–1121, 1994.
519. Orenstein WA, Wassilak SGF, DeForest A, et al. Seroprevalence of poliovirus antibodies among Massachusetts schoolchildren [abstract]. In: Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; September 28–October 1, 1988, 198. Abstract 512.
520. Kelley PW, Petruccioli BP, Stehr-Green P, et al. The susceptibility of young adult Americans to vaccine-preventable infections: a national serosurvey of US army recruits. *JAMA.* 266:2724–2729, 1991.
521. WHO Consultative Group. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. *Bull World Health Organ.* 40:925–945, 1969.
522. Oberhofer TR, Brown GC, Monto AS. Seroimmunity to poliomyelitis in an American community. *Am J Epidemiol.* 101:333–339, 1975.
523. Horstmann DM. Maxwell Finland lecture: viral vaccines and their ways. *Rev Infect Dis.* 1:502–516, 1979.
524. Cabasso VJ, Nozell H, Rueggsegger JM, et al. Poliovirus antibody three years after oral trivalent vaccine (Sabin strains). *J Pediatr.* 68:199–203, 1966.

525. Krugman RD, Hardy GE, Sellers C, et al. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. *Pediatrics*. 60:80–82, 1977.
526. Rousseau WE, Noble GR, Tegtmeier GE, et al. Persistence of poliovirus neutralizing antibodies eight years after immunization with live attenuated virus vaccine. *N Engl J Med*. 289:1357–1359, 1973.
527. Fortuin M, Maine N, Mendy M, et al. Measles, polio and tetanus toxoid antibody levels in Gambian children aged 3 to 4 years following routine vaccination. *Trans R Soc Trop Med Hyg*. 89:326–329, 1995.
528. Gamage D, Paliwadana P, Mach O, et al. Achieving High Seroprevalence against Polioviruses in Sri Lanka-Results from Serological Survey, 2014. *J Epidemiol Glob Health*. 2015;5(4 Suppl 1):S67-S71.
529. Stratton KR, Howe CJ, Johnston RB. *Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality*. Washington, DC: National Academy Press; 1994.
530. Terry L. *The Association of Cases of Poliomyelitis With the Use of Type 3 Oral Poliomyelitis Vaccines*. Washington, DC: US Department of Health, Education and Welfare; 1962.
531. WHO Collaborative Study Group. The relationship between persisting spinal paralysis and poliomyelitis vaccine: results of a ten-year enquiry. *Bull World Health Organ*. 60:231–242, 1982.
532. WHO Collaborative Study Group. The relationship between acute and persisting spinal paralysis and poliomyelitis vaccine (oral): results of a WHO enquiry. *Bull World Health Organ*. 53:319–331, 1976.
533. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. *Bull World Health Organ*. 66:739–746, 1988.
534. Sabin AB. Commentary on report on oral poliomyelitis vaccine. *JAMA*. 190:52–55, 1964.
535. Sabin AB. Paralytic poliomyelitis: old dogmas and new perspectives. *Rev Infect Dis*. 3:543–564, 1981.
536. Wyatt HV. Poliomyelitis in hypogammaglobulinemics. *J Infect Dis*. 128:802–806, 1973.
537. Prevots DR, Sutter RW, Strebel PM, et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. *Arch Pediatr Adolesc Med*. 148:479–485, 1994.
538. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. *JAMA*. 292:1696–1701, 2004.
539. Centers for Disease Control and Prevention. Imported vaccine-associated paralytic poliomyelitis: United States 2005. *MMWR Morb Mortal Wkly Rep*. 55:97–99, 2005.
540. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine

- followed by oral poliovirus vaccine: recommendations of the Advisory Committee on Immunization Practices. [Published correction appears in MMWR Morb Mortal Wkly Rep. 46:183, 1997.] MMWR Recomm Rep. 46(RR-3):1–25, 1997.
541. Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. *Infect Med.* 11:426, 429–430, 435–438, 1994.
 542. Strebel PM, Ion-Nedelcu N, Baughman AL, et al. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine: a risk factor for vaccine-associated paralytic poliomyelitis. *N Engl J Med.* 332:500–506, 1995.
 543. Izurieta HS, Sutter RW, Baughman AL, et al. Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections with vaccine. *Pediatr Infect Dis J.* 14:840–846, 1995.
 544. Andrus JK, Strebel PM, de Quadros CA, et al. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989–91. *Bull World Health Organ.* 73:33–40, 1995.
 545. Kohler KA, Banerjee K, Hlady WG, et al. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. *Bull World Health Organ.* 80:210–216, 2002.
 546. Vaccines and Biologicals. Report of the Interim Meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis, Geneva, November 9–11, 2002. Geneva, Switzerland: World Health Organization; 2003.
 547. Wilfert CM, Buckley RH, Mohanakumar T, et al. Persistent and fatal central-nervous-system echovirus infections in patients with agammaglobulinemia. *N Engl J Med.* 296:1485–1489, 1977.
 548. Ziegler JB, Penny R. Fatal echo 30 virus infection and amyloidosis in X-linked hypogammaglobulinemia. *Clin Immunol Immunopathol.* 3:347–352, 1975.
 549. Hodes DS, Espinoza DV. Temperature sensitivity of isolates of echovirus type 11 causing chronic meningoencephalitis in an agammaglobulinemic patient. *J Infect Dis.* 144:377, 1981.
 550. Gorson KC, Ropper AH. Nonpoliovirus poliomyelitis simulating Guillain-Barré syndrome. *Arch Neurol.* 58:1460–1464, 2001.
 551. Diop O, Burns CC, Wassilak SG, et al. Update on vaccine-derived polioviruses—worldwide, January 2014–March 2015. *MMWR Morb Mortal Wkly Rep.* 2015;64:640–646.
 552. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. *Annu Rev Microbiol.* 2005;59:587–635.
 553. Polio Global Eradication Initiative. Polio eradication and endgame strategic plan (2013–2018). 2013. Available at http://www.polioeradication.org/portals/0/document/resources/strategywork/endgamestratplan_20130414_eng.pdf
 554. World Health Organization. Polio Global Eradication Initiative. 16th Informal Consultation of the Global Polio Laboratory Network, 22–23 September 2010. Geneva,

Switzerland. 2010. Available at:

http://www.polioeradication.org/Portals/0/Document/Resources/GPLN_publications/GPLN_Meeting_recommendations_2010.pdf).

555. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, April 2011–June 2012. *MMWR Morb Mortal Wkly Rep.* 2012;61:741-746.
556. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. *PLoS One.* 2008;3:e3433.
557. Liang X, Zhang Y, Xu W, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. *J Infect Dis.* 2006;194:545-551.
558. Rakoto-Andrianarivelo M, Gumede N, Jegouic S, et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. *J Infect Dis.* 2008;197:1427-1435.
559. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2006–August 2007. *MMWR Morb Mortal Wkly Rep.* 2007;56:996-1001.
560. Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. *N Engl J Med.* 2010; 362:2360-2369.
561. Wassilak S, Pate MA, Wannemuehler K, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria, 2005–2009: emergence and widespread circulation in an underimmunized population. *J Infect Dis.* 2011;203:898-909.
562. Diop O, Burns CC, Wassilak SG, et al. Update on vaccine-derived polioviruses—worldwide, July 2012–December 2013. *MMWR Morb Mortal Wkly Rep.* 2014;63:242-248.
563. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, January 2008–June 2009. *MMWR Morb Mortal Wkly Rep.* 2009;58:1002-1006.
564. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2009–March 2011. *MMWR Morb Mortal Wkly Rep.* 2011;60:846-850.
565. Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. *N Engl J Med.* 2010;362:2360-2369.
566. Sutter RW, Prevots R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. *Infect Med.* 1994;11:426-438.
567. Khetsuriani N, Prevots DR, Quick L, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. *J Infect Dis.* 2003;188:1845-1852.
568. Li L, Ivanova O, Triki H, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. *J Infect Dis.* 2014;210:S368-S372.
569. Yong PF, Thaventhiran JE, Grimbacher B. “A rose is a rose is a rose,” but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? *Adv Immunol.* 2011;111:47-107.

570. Adu FD, Iber J, Bukbuk D, et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. *Virus Res.* 2007;127:17-25.
571. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002–June 2003. *MMWR Morb Mortal Wkly Rep.* 2003;52:913-916.
572. Korotkova EA, Park R, Cherkasova EA, et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. *J Virol.* 2003;77:12460-12465.
573. Shulman LM, Manor Y, Sofer D, et al. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. *PLoS One.* 2006;1:e69.
574. Cernáková B, Sobotová Z, Rovný I, et al. Isolation of vaccine-derived polioviruses in the Slovak Republic. *Eur J Clin Microbiol Infect Dis.* 2005;24:438-439.
575. Roivainen M, Blomqvist S, Al-Hello H, et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. *Euro Surveill.* 2010;15.
576. Eddy BE, Borman GS, Berkeley WH, et al. Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts. *Proc Soc Exp Biol Med.* 107:191–197, 1961.
577. Mortimer EA, Lepow ML, Gold E, et al. Long-term follow up of persons inadvertently inoculated with SV40 as neonates. *N Engl J Med.* 305:1517–1518, 1981.
578. Shah K, Nathanson N. Human exposure to SV40: review and comment. *Am J Epidemiol.* 103:1–12, 1976.
579. Lewis AM, Egan W. Meeting report: workshop on simian virus 40 (SV40): a possible human polyomavirus. *Biologicals.* 25:355–358, 1997.
580. Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. *JAMA.* 279:292–295, 1998.
581. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. *J Natl Cancer Inst.* 91:119–134, 1999.
582. Butel JS. Simian virus 40, poliovirus vaccines, and human cancer: research progress versus media and public interest. *Bull World Health Organ.* 78:195–197, 2000.
583. Stratton K, Almario DA, McCormick MC, (eds). *Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer.* Washington, DC: National Academy Press; 2002.
584. Paulin DL, DeCaprio JA. Is there a role for SV40 in human cancer? *J Clin Oncol.* 24: 4356–4365, 2006.
585. Engels EA. Does simian virus 40 causes non-Hodgkin lymphoma? A review of the laboratory and epidemiologic evidence. *Cancer Invest.* 23:529–536, 2005.

586. Engels EA, Katki HA, Nielson NM, et al. Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40. *J Natl Cancer Inst.* 95:532–539, 2003.
587. Rollison DE, Page WF, Crawford H, et al. Case-control study of cancer among US Army veterans exposed to simian virus 40–contaminated adenovirus vaccine. *Am J Epidemiol.* 160:317–324, 2004.
588. Uhari M, Rantala M, Niemela M. Cluster of childhood Guillain-Barré cases after an oral polio vaccine campaign. *Lancet.* 2:440–441, 1989.
589. Kinnunen E, Farkkila M, Hovi T, et al. Incidence of Guillain-Barré syndrome during a nationwide oral poliovirus campaign. *Neurology.* 39:1034–1036, 1989.
590. Rantala H, Cherry JD, Shields WD, et al. Epidemiology of Guillain-Barré syndrome in children: relationship of oral polio vaccine administration to occurrence. *J Pediatr.* 124:220–223, 1994.
591. Kinnunen E, Junttila O, Haukka J, et al. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré syndrome. *Am J Epidemiol.* 147:69–73, 1998.
592. American Academy of Pediatrics. Poliovirus infections. In: Peter G, (ed). 1997 Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 1997, 424–433.
593. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 49(RR-5):1–22, 2000.
594. Salisbury DM, Begg NT, (eds). *Immunisation Against Infectious Disease*, 1996. Department of Health, Welsh Office, Scottish Office Home and Health Department, DHHS (Northern Ireland). London, England: Her Majesty's Stationery Office; 1996.
595. Onorato IM, Strebel PM, Sutter RW. Immunizations, vaccine-preventable diseases, and HIV infection. In: Wormser GP, (ed). *AIDS and Other Manifestations of HIV Infection*, 3rd ed. Philadelphia, PA: Lippincott-Raven; 1998, 745–758.
596. Ryder RW, Oxtoby MJ, Mvula M, et al. Safety and immunogenicity of bacille Calmette-Guérin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. *J Pediatr.* 122:697–702, 1993.
597. Vernon A, Okwo B, Lubamba N, et al. Paralytic poliomyelitis and HIV infection in Kinshasa, Zaire. In: *Proceedings of the Sixth International Conference on AIDS*. San Francisco, CA; June 20–24, 1990.
598. Ion-Nedelcu N, Dobrescu A, Strebel PM, et al. Vaccine-associated paralytic poliomyelitis and HIV infection [letter]. *Lancet.* 343:51–52, 1994.
599. Chitsike I, van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. *BMJ.* 318:841–843, 1999.

600. Hennessey KA, Lago H, Diomande E, et al. Poliovirus vaccine shedding among persons with HIV in Abidjan, Côte d'Ivoire. *J Infect Dis.* 192:2124–2128, 2005.
601. Pavlov DN, Van Zyl WB, Van Heerden J, et al. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa. *J Appl Microbiol.* 101:1367–1379, 2006.
602. Slater PE, Orenstein WA, Morag A, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. *Lancet.* 335:1192–1198, 1990.
603. Harjulehto-Mervaala T, Aro T, Hiilesmaa VK, et al. Oral polio vaccination during pregnancy: no increase in the occurrence of malformations. *Am J Epidemiol.* 138:407–414, 1993.
604. Harjulehto-Mervaala T, Aro T, Hiilesmaa VK, et al. Oral polio vaccination during pregnancy: lack of impact on fetal development and perinatal outcome. *Clin Infect Dis.* 18:414–420, 1994.
605. Myaux JA, Unicom L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. *Pediatr Infect Dis J.* 15:204–209, 1996.
606. Sartono E, Lisse IM, Terveer EM, et al. Oral polio vaccine influences the immune response to BCG vaccination: a natural experiment. *PLoS One.* 5:e10328, 2010
607. Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Influence of *Mycobacterium bovis* bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. *J Immunol.* 168:919–925, 2002.
608. Steele AD, De Vos B, Tumbo J, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. *Vaccine.* 28:6542–6548, 2010.
609. Zaman K, Sack DA, Yunus M, et al; Bangladeshi Rotavirus Vaccine Study Group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. *Vaccine.* 27:1333–1339, 2009.
610. Cameron JC, Walsh D, Finlayson AR, et al. Oral polio vaccine and intussusception: a data linkage study using records for vaccination and hospitalization. *Am J Epidemiol.* 163:528–533, 2006.
611. Galindo Sardinias MA, Zambrano Cardenas A, Coutin Marie G, et al. Lack of association between intussusception and oral poliovirus vaccine in Cuba. *Eur J Epidemiol.* 17:783–787, 2001.
612. World Health Organization. Polio vaccines: WHO position paper, January 2014. *Wkly Epidemiol Rec.* 2014;89:73–92.
613. Peter G, (ed). 1997 Red Book: Report of the Committee on Infectious Diseases, Elk Grove Village, IL: American Academy of Pediatrics; 1997.

614. Modlin JF, Halsey NA, Thoms ML, et al. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine–live attenuated oral poliovirus vaccine immunization schedules. *J Infect Dis.* 175(Suppl 1):S228–S234, 1997.
- 614a. Sutter RW, Bahl S, Deshpande JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. *Lancet.* 2015;386:2413-2421.
- 614b. O’Ryan M, Bandyopadhyay AS, Villena R, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. *Lancet Infect Dis.* 2015 15:1273-1282.
615. Lasch EE, Abed Y, Marcus O, et al. Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country: five years after. *Dev Biol Stand.* 65:137–143, 1985.
616. Faden H, Modlin JF, Thoms ML, et al. Comparative evaluation of immunization with live attenuated and enhanced-potency poliovirus vaccines in childhood: systemic and local immune response. *J Infect Dis.* 162:1291–1297, 1990.
617. Blatter MM, Starr S. Safety and Immunogenicity of a Combination DTP/eIPV Vaccine Presented in a Dual Chamber Syringe, in 2-Month-Old Infants. Swiftwater, PA: Connaught Laboratories; 1993.
618. Halsey NA, Blatter MM, Bader G. Safety and Immunogenicity of a Combination DTP/IPV Vaccine Administered to Infants in a Dual Chamber Syringe. Swiftwater, PA: Connaught Laboratories; 1994.
619. Halsey N, Blatter M, Bader G, et al. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four-, and six-month-old infants with combination *Haemophilus influenzae* type b/hepatitis B vaccine. *Pediatr Infect Dis J.* 16:675–679, 1997.
620. Ion-Nedelcu N, Strebel PM, Toma F, et al. Sequential use of inactivated and oral poliovirus vaccines: Dolj district, Romania, 1992–1994. *J Infect Dis.* 175(Suppl 1):S241–S246, 1997.
621. Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. *Lancet.* 341:1545–1550, 1993.
622. Tulchinsky T, Abed Y, Handsher R, et al. Successful control of poliomyelitis by a combined OPV/IPV polio vaccine program in the West Bank and Gaza, 1978–1993. *Isr J Med Sci.* 30:489–494, 1994.
623. Goldblum N, Gerichter CB, Tulchinsky TH, et al. Poliomyelitis control in Israel, the West Bank and Gaza Strip: changing strategies with the goal of eradication in an endemic area. *Bull World Health Organ.* 72:783–796, 1994.
624. Swartz TA, Handsher R. Israel in the elimination phase of poliomyelitis: achievements and remaining problems. *Public Health Rev.* 21:99–106, 1993–1994.

625. Rishpon S. Recent improvements in polio and pertussis vaccination policy in Israel, 2005. *Isr Med Assoc J.* 8:319–321, 2006.
626. Asturias EJ, Dueger EL, Omer SB, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. *J Infect Dis.* 196:692–698, 2007.
627. Hanlon P, Hanlon L, Marsh V, et al. Serological comparisons of approaches to polio vaccination in The Gambia. *Lancet.* 1:800–801, 1987.
628. Sutter RW, Suleiman AJ, Malankar PG, et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. *J Infect Dis.* 175(Suppl 1):S235–S240, 1997.
629. Faden H, Duffy L, Sun M, et al. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. *J Infect Dis.* 168:452–454, 1993.
630. Yoshida H, Horie H, Matsuura K, et al. Prevalence of vaccine-derived poliovirus in the environment. *J Gen Virol.* 83:1107–1110, 2002.
631. Kew OM, Nottay BK, Hatch MH, et al. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. *J Gen Virol.* 56(Pt 2):337–347, 1981.
632. Cann AJ, Stanway G, Hughes PJ, et al. Reversion to virulence of the live attenuated Sabin type 3 oral poliovirus vaccine. *Nucleic Acids Res.* 12:7787–7792, 1984.
633. Pollard SR, Dunn G, Cammack N, et al. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. *J Virol.* 63:4949–4951, 1989.
634. Evans DM, Dunn G, Minor PD, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of Sabin type 3 poliovaccine genome. *Nature.* 314:548–550, 1985.
635. Dunn G, Begg NT, Cammack N, et al. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. *J Med Virol.* 32:92–95, 1990.
636. Tatem JM, Weeks-Levy C, Mento SJ, et al. Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees. *J Med Virol.* 35:101–109, 1991.
637. Ogra PL, Faden HS, Abraham R, et al. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. *J Infect Dis.* 161:191–194, 1991.
638. Abraham R, Minor P, Dunn G, et al. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. *J Infect Dis.* 168:1105–1109, 1993.
639. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. *Vaccine.* 14:735–746, 1996.

640. De-Xiang D, Xi-Min H, Wan-Jun L, et al. Immunisation of neonates with trivalent oral poliomyelitis vaccine (Sabin). *Bull World Health Organ.* 64:853–860, 1986.
641. Halsey N, Galazka A. The efficacy of DTP and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. *Bull World Health Organ.* 63:1151–1169, 1985.
642. Galazka AM, Lauer BA, Henderson RH, Keja J. Indications and contraindications for vaccines used in the Expanded Programme on Immunization. *Bull World Health Organ.* 62:357–366, 1984.
643. Weckx LY, Schmidt BJ, Hermann AA, et al. Early immunization of neonates with trivalent oral poliovirus vaccine. *Bull World Health Organ.* 70:85–91, 1992.
644. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. *Wkly Epidemiol Rec.* 85:213–228, 2010.
645. Mir F, Quadri F, Mach O, et al. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial. *Lancet Infect Dis.* 2015;15:889-897.
646. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. *Mol Ther.* 2007;15:651-659.
647. Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. *Science.* 1991;252:854-856.
648. Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. *Nat Biotechnol.* 2012;30:658-670.
649. Andtbacka RH, Curti BD, Kaufman H, et al. CALM study: a phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. *ASCO Meeting Abstracts* 2014;32:3031.
650. Brown MC, Gromeier M. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. *Curr Opin Virol.* 2015;13:81-85.
651. Coffin RS. From virotherapy to oncolytic immunotherapy: where are we now? *Curr Opin Virol.* 2015;13:93-100.
652. Dobrikova EY, Goetz C, Walters RW, et al. Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in *Macaca fascicularis*. *J Virol.* 2012;86:2750-2759.
653. Masson D, Jarry A, Baury B, et al. Overexpression of the CD155 gene in human colorectal carcinoma. *Gut.* 2001;49:236-240.
654. Sloan KE, Stewart JK, Treloar AF, et al. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. *Cancer Res.* 2005;65:10930-10937.
655. Brown MC, Dobrikova EY, Dobrikov MI, et al. Oncolytic polio virotherapy of cancer. *Cancer.* 2014;120:3277-3286.

656. Centers for Disease Control and Prevention. Progress toward interrupting wild poliovirus transmission—worldwide, January 2010–March 2011. *MMWR Morb Mortal Wkly Rep.* 2011;60:582-586.
657. Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission—worldwide, January 2011–March 2012. *MMWR Morb Mortal Wkly Rep.* 2012;61:353-357.
658. Centers for Disease Control and Prevention. Progress toward eradication of polio—worldwide, January 2011–March 2013. *MMWR Morb Mortal Wkly Rep.* 2013;62:335-338.
659. Moturi EK, Porter KA, Wassilak SG, et al. Progress toward polio eradication—worldwide, 2013–2014. *MMWR Morb Mortal Wkly Rep.* 2014;63:468-472.
660. Hagan JE, Wassilak SG, Craig AS, et al. Progress toward polio eradication—worldwide, 2014–2015. *MMWR Morb Mortal Wkly Rep.* 2015;64:527-531.
661. Goodman T, Dalmiya N, de Benoist B, et al. Polio as a platform: using national immunization days to deliver vitamin A supplements. *Bull World Health Organ.* 78:305–314, 2000.
662. Ching P, Birmingham M, Goodman T, et al. The childhood mortality impact of integrating vitamin A supplements with immunization campaigns. *Am J Public Health.* 90:1526–1529, 2000.
663. World Health Organization. WHO/UNICEF coverage estimates for 1980-2015, as of 15 July 2016. Coverage Estimate Series Excel workbook. http://www.who.int/entity/immunization/monitoring_surveillance/data/coverage_estimates_series.xls?ua=1.
664. Birmingham ME, Aylward RB, Cochi SL, et al. National immunization days: state of the art. *J Infect Dis.* 175(Suppl 1):S183–S188, 1997.
665. Expanded Programme on Immunization. Field Guide for Supplementary Activities Aimed at Achieving Polio Eradication. Geneva, Switzerland: World Health Organization; 1997.
666. Reichler MR, Kharabsheh S, Rhodes P, et al. Increased immunogenicity of oral poliovirus vaccine administered in mass vaccination campaigns compared with the routine vaccination program in Jordan. *J Infect Dis.* 175(Suppl 1):S198–S204, 1997.
667. Richardson G, Linkins RW, Eames M, et al. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programs. *Bull World Health Organ.* 73:769–777, 1995.
668. Deming MS, Linkins RW, Jaiteh KO, et al. The clinical efficacy of trivalent oral polio vaccine in The Gambia by season of vaccine administration. *J Infect Dis.* 175(Suppl 1): S254–S257, 1997.
669. Cochi SL, Hull HF, Sutter RW, et al. Global poliomyelitis eradication initiative: status report. *J Infect Dis.* 175(Suppl 1):1–292, 1997.

670. Hagan JE, Wassilak SG, Carig AS, et al. Progress towards polio eradication worldwide, 2014-2015. *Wkly Epidemiol Rec.* 2015;90:253-259.
671. World Health Organization. Monitoring progress towards global polio eradication: poliovirus surveillance, 2009–2010. *Wkly Epidemiol Rec.* 86:153–160, 2011.
672. World Health Organization. Poliomyelitis in Tajikistan—update. *Wkly Epidemiol Rec.* 2010;85:165-166.
673. World Health Organization. Progress towards global interruption of wild poliovirus transmission, January 2011–March 2012. *Wkly Epidemiol Rec.* 2012;87:195-200.
674. Polio Global Eradication Initiative. Cases of Wild Poliovirus by Country and Year. Available at:
<http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx>
- 674a. Previsani N, Tangermann RH, Tallis G, et al. World Health Organization guidelines for containment of poliovirus following type-specific polio eradication—worldwide, 2015. *MMWR Morb Mortal Wkly Rep.* 2015;64:913-917.
675. Meeting report. WHO Strategic Advisory Group of Experts (SAGE). *Biologicals.* 2008;36:336-343.
676. World Health Organization. SAGE working group on polio (established August 2008). Available at: http://www.who.int/immunization/sage/sage_wg_polio_oct08/en/index.html
677. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012—conclusions and recommendations. *Wkly Epidemiol Rec.* 2013;88:1-16.
678. Polio Global Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013-2018. Available at:
http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/EndGameStratPlan_WHAversion.pdf
679. Centers for Disease Control and Prevention. Progress toward the global interruption of wild poliovirus type 2 transmission, 1999. *MMWR Morb Mortal Wkly Rep.* 1999;48:736-738, 747.
680. Aylward RB, Cochi SL. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. *Bull World Health Organ.* 2004;82:40-46.
681. de Oliveira LH, Struchiner CJ. Vaccine-associated paralytic poliomyelitis in Brazil, 1989-1995. *Rev Panam Salud Publica.* 2000;7:219-224.
682. de Oliveira LH, Struchiner CJ. Vaccine-associated paralytic poliomyelitis: a retrospective cohort study of acute flaccid paralyzes in Brazil. *Int J Epidemiol.* 2000;29:757-763.
683. Agol VI. Vaccine-derived polioviruses. *Biologicals.* 2006;34:103-108.
684. John TJ, Vashishtha VM. Eradicating poliomyelitis: India’s journey from hyperendemic to polio-free status. *Indian J Med Res.* 2013;137:881-894.

685. Esteve-Jaramillo A, Richardson Lopez-Collada VL. [Towards the eradication of poliomyelitis: Mexico's achievements and challenges] [in Spanish]. *Salud Publica Mex.* 2012;54:537-543.
686. Mas Lago P, Diaz J, Diaz Gonzalez M, et al. [Isolates of poliovirus vaccine and immune response to different doses of oral polio vaccine] [in Spanish]. *Rev Cubana Med Trop.* 2005;57:111-119.
687. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. *N Engl J Med.* 2013;368:416-424.
688. Estivariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. *Lancet Infect Dis.* 2012; 12:128-135.
689. Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. *J Virol.* 2013;87:4907-4922.
690. Vaccines and Biologicals. Report of an Informal Consultation on the Identification and Management of Vaccine-derived Polioviruses (VDPVs). Geneva, Switzerland: World Health Organization; 2004.
691. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. *Risk Anal.* 26:1471–1505, 2006.
692. Fine PE, Ritchie S. Perspective: determinants of severity of poliovirus outbreaks in the post eradication era. *Risk Anal.* 26:1533–1540, 2006.
693. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. *Science.* 297:1016–1018, 2002.
694. Polio Global Eradication Initiative. Cessation of Routine Oral Polio Vaccine (OPV) Use After Global Polio Eradication: Framework for National Policy Makers in OPV-using Countries. Geneva, Switzerland: World Health Organization; 2005.
695. Fine PE, Sutter RW, Orenstein WA. Stopping a polio outbreak in the post-eradication era. *Dev Biol (Basel).* 105:129–147, 2001.
696. World Health Organization. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries: WHO position paper. *Wkly Epidemiol Rec.* 78:241–250, 2004.
697. World Health Organization. Inactivated poliovirus vaccines (IPV) following oral poliovirus vaccine (OPV) cessation: supplemental WHO position paper. *Wkly Epidemiol Rec.* 81:137–144, 2006.
698. Supply Division. Summary Report: IPV Request for Commercial Indication. Copenhagen, Denmark: UNICEF; 2003.
699. Polio Global Eradication Initiative. WHO Global Action Plan to Minimize Poliovirus Facility-Associated Risk in the Post Eradication/OPV Era. Geneva, Switzerland: World Health Organization; 2008.

700. Polio Global Eradication Initiative. Polio Operations and Research Department. GAPIII- WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of OPV use. Edited version, posted on 22 July 2015. Available at: <http://www.polioeradication.org/ResourceLibrary/Posteradicationpolicydocuments.aspx#sthash.M3dfXw3v.dpuf>
701. Heymann DL, Sutter RW, Aylward BA. A global call for new polio vaccines. *Nature*. 434:699–700, 2005.
702. Aylward BA, Sutter RW, Heymann DL. OPV cessation: the final step to a “polio-free” world. *Science*. 310:625–626, 2005.
703. Arita I, Nakane M, Fenner F. Is polio eradication realistic? *Science*. 312:852–853, 2006.
704. Roberts L. Polio eradication: is it time to give up? *Science*. 312:832–835, 2006.
705. Smith J, Leke R, Adams A, et al. Certification of polio eradication: process and lessons learned. *Bull World Health Organ*. 2004;82:24-30.
706. Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. *N Engl J Med*. 1980;303:1263-1273.
707. World Health Organization. Expanded Programme on Immunization—Certification of poliomyelitis eradication—the Americas, 1994. *Wkly Epidemiol Rec*. 1994;69:293-295.
708. Robbins FC, de Quadros CA. Certification of the eradication of indigenous transmission of wild poliovirus in the Americas. *J Infect Dis*. 1997;175(Suppl. 1):S281-S285.
709. Chiba Y, Murakami H, Kobayashi M, et al. A case of poliomyelitis associated with infection of wild poliovirus in Qinghai Province, China, in October 1999. *Jpn J Infect Dis*. 2000;53:135-136.
710. World Health Organization. Wild poliovirus imported into Qinghai province, China. *Wkly Epidemiol Rec*. 2000;75:55-57.
711. Kojouharova M, Zuber PL, Gyurova S, et al. Importation and circulation of poliovirus in Bulgaria in 2001. *Bull World Health Organ*. 2003;81:476-481.
712. World Health Organization. Certification of poliomyelitis eradication: Western Pacific Region. *Wkly Epidemiol Rec*. 2000;75:399-400.
713. O’Connor PM, Allison R, Thapa A, et al. Update on polio eradication in the World Health Organization South-East Asia Region, 2013. *J Infect Dis*. 2014;210:S216-S224.
714. Adams A, Boualam L, Diorditsa S, et al. Maintaining polio-free certification in the World Health Organization Western Pacific Region for over a decade. *J Infect Dis*. 2014;210:S259-S267.
715. Khetsuriani N, Pfeifer D, Deshevoi S, et al. Challenges of maintaining polio-free status of the European Region. *J Infect Dis*. 2014;210 Suppl 1:S194-S207.
716. World Health Organization. Progress towards global interruption of wild poliovirus transmission, January 2012–March 2013. *Wkly Epidemiol Rec*. 2013;88:181-187.

717. Sutter RW, Platt L, Mach O, et al. The new polio eradication end game: rationale and supporting evidence. *J Infect Dis.* 2014;210:S434-S438.
718. World Health Organization. Global action plan for laboratory containment of wild polioviruses, 2nd ed. Geneva, Switzerland: World Health Organization; 2003.
719. Dowdle WR, Wolff C, Sanders R, et al. Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? *Bull World Health Organ.* 2004;82:59-62.
720. Wolff C, Roesel S, Lipskaya G, et al. Progress toward laboratory containment of poliovirus after polio eradication. *J Infect Dis.* 2014;210:S454-S458.
721. World Health Organization. Global action plan for laboratory containment of wild polioviruses. Geneva, Switzerland: World Health Organization; 1999.
722. World Health Organization. Report of the first meeting of the Global Commission for the Certification of Eradication of Polio. Geneva, Switzerland: World Health Organization; 1995.
723. Polio Global Eradication Initiative. World Health Organization. WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of OPV use (GAPIII). 2015. Available at: http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf
724. Centers for Disease Control and Prevention. National laboratory inventory for global poliovirus containment—United States, November 2003. *MMWR Morb Mortal Wkly Rep.* 2004;53:457-459.
725. World Health Organization. Completion of national laboratory inventories for wild poliovirus containment—WHO Western Pacific Region, December 2008. *Wkly Epidemiol Rec.* 2009;84:373-382.
726. Pallansch M, Staples M. Wild poliovirus found in stored potential infectious materials. *Polio Lab Netw Quart Update.* 2002;8:1-2.